{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:57:48Z","timestamp":1794272268372,"version":"4.9.0"},"reference-count":421,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02850-x","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T23:01:58Z","timestamp":1784502118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets"],"prefix":"10.1038","volume":"11","author":[{"given":"Kun-Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Zhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Han","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7807-3492","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2850_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin"},{"key":"2850_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41392-020-00300-w","volume":"5","author":"H Song","year":"2020","unstructured":"Song, H. et al. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct. Target. Ther. 5, 193 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2850_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/leu.2013.248","volume":"28","author":"DA Landau","year":"2014","unstructured":"Landau, D. A., Carter, S. L., Getz, G. & Wu, C. J. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 28, 34\u201343 (2014).","journal-title":"Leukemia"},{"key":"2850_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"2850_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/neuonc\/noab269","volume":"24","author":"YA Yabo","year":"2022","unstructured":"Yabo, Y. A., Niclou, S. P. & Golebiewska, A. Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma. Neuro Oncol 24, 669\u2013682 (2022).","journal-title":"Neuro Oncol"},{"key":"2850_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306\u2013313 (2012).","journal-title":"Nature"},{"key":"2850_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23\u201328 (1976).","journal-title":"Science"},{"key":"2850_CR8","first-page":"2651","volume":"38","author":"IJ Fidler","year":"1978","unstructured":"Fidler, I. J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 38, 2651\u20132660 (1978).","journal-title":"Cancer Res"},{"key":"2850_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2850_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0453-8","volume":"15","author":"C Hiley","year":"2014","unstructured":"Hiley, C., De Bruin, E. C., McGranahan, N. & Swanton, C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol 15, 453 (2014).","journal-title":"Genome Biol"},{"key":"2850_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.molonc.2010.04.010","volume":"4","author":"NE Navin","year":"2010","unstructured":"Navin, N. E. & Hicks, J. Tracing the tumor lineage. Mol. Oncol. 4, 267\u2013283 (2010).","journal-title":"Mol. Oncol."},{"key":"2850_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","volume":"153","author":"LA Garraway","year":"2013","unstructured":"Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17\u201337 (2013).","journal-title":"Cell"},{"key":"2850_CR13","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546\u20131558 (2013).","journal-title":"Science"},{"key":"2850_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501 (2014).","journal-title":"Nature"},{"key":"2850_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/gm247","volume":"3","author":"N Navin","year":"2011","unstructured":"Navin, N. & Hicks, J. Future medical applications of single-cell sequencing in cancer. Genome Med 3, 31 (2011).","journal-title":"Genome Med"},{"key":"2850_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nature14590","volume":"523","author":"JD Buenrostro","year":"2015","unstructured":"Buenrostro, J. D. et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 523, 486\u2013490 (2015).","journal-title":"Nature"},{"key":"2850_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nmeth.1315","volume":"6","author":"F Tang","year":"2009","unstructured":"Tang, F. et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat. Methods 6, 377\u2013382 (2009).","journal-title":"Nat. Methods"},{"key":"2850_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-022-00990-4","volume":"7","author":"Q Jia","year":"2022","unstructured":"Jia, Q. et al. High-throughput single-\u0441ell sequencing in cancer research. Signal Transduct. Target. Ther. 7, 145 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2850_CR19","doi-asserted-by":"publisher","first-page":"6813","DOI":"10.1021\/ac901049w","volume":"81","author":"DR Bandura","year":"2009","unstructured":"Bandura, D. R. et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal. Chem. 81, 6813\u20136822 (2009).","journal-title":"Anal. Chem."},{"key":"2850_CR20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41568-024-00734-2","volume":"24","author":"L Laplane","year":"2024","unstructured":"Laplane, L. & Maley, C. C. The evolutionary theory of cancer: challenges and potential solutions. Nat. Rev. Cancer. 24, 718\u2013733 (2024).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR21","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"2850_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbcan.2017.01.003","volume":"1867","author":"A Davis","year":"2017","unstructured":"Davis, A., Gao, R. & Navin, N. Tumor evolution: linear, branching, neutral or punctuated? Biochim. Biophys. Acta Rev. Cancer. 1867, 151\u2013161 (2017).","journal-title":"Biochim. Biophys. Acta Rev. Cancer."},{"key":"2850_CR23","doi-asserted-by":"publisher","first-page":"21083","DOI":"10.1073\/pnas.1320659110","volume":"110","author":"X Ni","year":"2013","unstructured":"Ni, X. et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc. Natl. Acad. Sci. USA 110, 21083\u201321088 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nbt.2892","volume":"32","author":"JG Lohr","year":"2014","unstructured":"Lohr, J. G. et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat. Biotechnol. 32, 479\u2013484 (2014).","journal-title":"Nat. Biotechnol."},{"key":"2850_CR25","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","volume":"158","author":"N Aceto","year":"2014","unstructured":"Aceto, N. et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110\u20131122 (2014).","journal-title":"Cell"},{"key":"2850_CR26","doi-asserted-by":"publisher","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2850_CR27","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"S-J Dawson","year":"2013","unstructured":"Dawson, S.-J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199\u20131209 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2850_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/nrc2013","volume":"6","author":"LMF Merlo","year":"2006","unstructured":"Merlo, L. M. F., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer. 6, 924\u2013935 (2006).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR29","doi-asserted-by":"publisher","first-page":"e108389","DOI":"10.15252\/embj.2021108389","volume":"40","author":"R Vendramin","year":"2021","unstructured":"Vendramin, R., Litchfield, K. & Swanton, C. Cancer evolution: Darwin and beyond. EMBO J 40, e108389 (2021).","journal-title":"EMBO J"},{"key":"2850_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s12038-012-9235-1","volume":"37","author":"M Morange","year":"2012","unstructured":"Morange, M. What history tells us XXVIII. What is really new in the current evolutionary theory of cancer? J. Biosci. 37, 609\u2013612 (2012).","journal-title":"J. Biosci."},{"key":"2850_CR31","first-page":"327","volume":"14","author":"L Foulds","year":"1954","unstructured":"Foulds, L. The experimental study of tumor progression: a review. Cancer Res 14, 327\u2013339 (1954).","journal-title":"Cancer Res"},{"key":"2850_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1242\/jcs.025742","volume":"121","author":"T Boveri","year":"2008","unstructured":"Boveri, T. Concerning the origin of malignant tumours by theodor boveri. Translated and annotated by Henry Harris. J. Cell Sci. 121, 1\u201384 (2008).","journal-title":"J. Cell Sci."},{"key":"2850_CR33","first-page":"957","volume":"21","author":"TS Hauschka","year":"1961","unstructured":"Hauschka, T. S. The chromosomes in ontogeny and oncogeny. Cancer Res 21, 957\u2013974 (1961).","journal-title":"Cancer Res"},{"key":"2850_CR34","unstructured":"Ford, C. E. in Cytogenet. Cell Cultural International Society for Cell Biology Symposia (ed R. J. C. Harris) 27-45 (Academic Press, 1964)."},{"key":"2850_CR35","first-page":"2259","volume":"44","author":"GH Heppner","year":"1984","unstructured":"Heppner, G. H. Tumor heterogeneity. Cancer Res 44, 2259\u20132265 (1984).","journal-title":"Cancer Res"},{"key":"2850_CR36","first-page":"3174","volume":"38","author":"DL Dexter","year":"1978","unstructured":"Dexter, D. L. et al. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38, 3174\u20133181 (1978).","journal-title":"Cancer Res"},{"key":"2850_CR37","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217","volume":"72","author":"C Swanton","year":"2012","unstructured":"Swanton, C. Intratumor heterogeneity: evolution through space and time. Cancer Res 72, 4875\u20134882 (2012).","journal-title":"Cancer Res"},{"key":"2850_CR38","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730\u2013737 (1997).","journal-title":"Nat. Med."},{"key":"2850_CR39","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M. et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983\u20133988 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.semcancer.2017.02.011","volume":"44","author":"C Peitzsch","year":"2017","unstructured":"Peitzsch, C., Tyutyunnykova, A., Pantel, K. & Dubrovska, A. Cancer stem cells: the root of tumor recurrence and metastases. Semin. Cancer Biol. 44, 10\u201324 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"2850_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature01593","volume":"423","author":"T Reya","year":"2003","unstructured":"Reya, T. et al. A role for wnt signalling in self-renewal of haematopoietic stem cells. Nature 423, 409\u2013414 (2003).","journal-title":"Nature"},{"key":"2850_CR42","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature01587","volume":"423","author":"I-K Park","year":"2003","unstructured":"Park, I.-K. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302\u2013305 (2003).","journal-title":"Nature"},{"key":"2850_CR43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature01572","volume":"423","author":"J Lessard","year":"2003","unstructured":"Lessard, J. & Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255\u2013260 (2003).","journal-title":"Nature"},{"key":"2850_CR44","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/81390","volume":"6","author":"B Varnum-Finney","year":"2000","unstructured":"Varnum-Finney, B. et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat. Med. 6, 1278\u20131281 (2000).","journal-title":"Nat. Med."},{"key":"2850_CR45","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0960-9822(06)00293-4","volume":"7","author":"D Henrique","year":"1997","unstructured":"Henrique, D. et al. Maintenance of neuroepithelial progenitor cells by Delta-Notch signalling in the embryonic chick retina. Curr. Biol. 7, 661\u2013670 (1997).","journal-title":"Curr. Biol."},{"key":"2850_CR46","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1158\/0008-5472.CAN-04-1844","volume":"64","author":"MC Smith","year":"2004","unstructured":"Smith, M. C. et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64, 8604\u20138612 (2004).","journal-title":"Cancer Res"},{"key":"2850_CR47","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1096\/fj.03-0935fje","volume":"18","author":"M Darash-Yahana","year":"2004","unstructured":"Darash-Yahana, M. et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 18, 1240\u20131242 (2004).","journal-title":"FASEB J"},{"key":"2850_CR48","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nrc1694","volume":"5","author":"T Brabletz","year":"2005","unstructured":"Brabletz, T. et al. Opinion: Migrating cancer stem cells\u2014an integrated concept of malign ant tumour progression. Nat. Rev. Cancer. 5, 744\u2013749 (2005).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR49","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645\u2013648 (1994).","journal-title":"Nature"},{"key":"2850_CR50","doi-asserted-by":"publisher","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","volume":"65","author":"D Fang","year":"2005","unstructured":"Fang, D. et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65, 9328\u20139337 (2005).","journal-title":"Cancer Res"},{"key":"2850_CR51","first-page":"5821","volume":"63","author":"SK Singh","year":"2003","unstructured":"Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 63, 5821\u20135828 (2003).","journal-title":"Cancer Res"},{"key":"2850_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature05384","volume":"445","author":"L Ricci-Vitiani","year":"2007","unstructured":"Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111\u2013115 (2007).","journal-title":"Nature"},{"key":"2850_CR53","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1200\/JCO.2007.15.1472","volume":"26","author":"NJ Maitland","year":"2008","unstructured":"Maitland, N. J. & Collins, A. T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 26, 2862\u20132870 (2008).","journal-title":"J. Clin. Oncol."},{"key":"2850_CR54","first-page":"a041270","volume":"12","author":"SP Rowbotham","year":"2022","unstructured":"Rowbotham, S. P. et al. Lung cancer stem cells and their clinical implications. Cold Spring Harb. Perspect. Med. 12, a041270 (2022).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2850_CR55","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1517\/14712598.7.4.431","volume":"7","author":"LL Song","year":"2007","unstructured":"Song, L. L. & Miele, L. Cancer stem cells\u2014an old idea that\u2019s new again: implications for the diagnosis and treatment of breast cancer. Expert Opin. Biol. Ther. 7, 431\u2013438 (2007).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2850_CR56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature04372","volume":"439","author":"M Shackleton","year":"2006","unstructured":"Shackleton, M. et al. Generation of a functional mammary gland from a single stem cell. Nature 439, 84\u201388 (2006).","journal-title":"Nature"},{"key":"2850_CR57","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature04496","volume":"439","author":"J Stingl","year":"2006","unstructured":"Stingl, J. et al. Purification and unique properties of mammary epithelial stem cells. Nature 439, 993\u2013997 (2006).","journal-title":"Nature"},{"key":"2850_CR58","doi-asserted-by":"publisher","first-page":"E190","DOI":"10.1038\/35087138","volume":"3","author":"A Schulze","year":"2001","unstructured":"Schulze, A. & Downward, J. Navigating gene expression using microarrays\u2014a technology review. Nat. Cell Biol. 3, E190\u2013E195 (2001).","journal-title":"Nat. Cell Biol."},{"key":"2850_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrg2626","volume":"11","author":"ML Metzker","year":"2010","unstructured":"Metzker, M. L. Sequencing technologies - the next generation. Nat. Rev. Genet. 11, 31\u201346 (2010).","journal-title":"Nat. Rev. Genet."},{"key":"2850_CR60","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature03959","volume":"437","author":"M Margulies","year":"2005","unstructured":"Margulies, M. et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437, 376\u2013380 (2005).","journal-title":"Nature"},{"key":"2850_CR61","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1126\/science.1117389","volume":"309","author":"J Shendure","year":"2005","unstructured":"Shendure, J. et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309, 1728\u20131732 (2005).","journal-title":"Science"},{"key":"2850_CR62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jtho.2022.11.006","volume":"18","author":"NB Larson","year":"2023","unstructured":"Larson, N. B., Oberg, A. L., Adjei, A. A. & Wang, L. A clinician\u2019s guide to bioinformatics for next-generation sequencing. J. Thorac. Oncol. 18, 143\u2013157 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2850_CR63","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.canlet.2012.10.018","volume":"340","author":"LR Patel","year":"2013","unstructured":"Patel, L. R., Nykter, M., Chen, K. & Zhang, W. Cancer genome sequencing: understanding malignancy as a disease of the genome, its conformation, and its evolution. Cancer Lett 340, 152\u2013160 (2013).","journal-title":"Cancer Lett"},{"key":"2850_CR64","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714\u2013726 (2013).","journal-title":"Cell"},{"key":"2850_CR65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/jhg.2013.114","volume":"59","author":"B Rabbani","year":"2014","unstructured":"Rabbani, B., Tekin, M. & Mahdieh, N. The promise of whole-exome sequencing in medical genetics. J. Hum. Genet. 59, 5\u201315 (2014).","journal-title":"J. Hum. Genet."},{"key":"2850_CR66","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1016\/j.cell.2023.07.024","volume":"186","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. Archival single-cell genomics reveals persistent subclones during DCIS progression. Cell 186, 3968\u20133982.e3915 (2023).","journal-title":"Cell"},{"key":"2850_CR67","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature09807","volume":"472","author":"N Navin","year":"2011","unstructured":"Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90\u201394 (2011).","journal-title":"Nature"},{"key":"2850_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00643-4","volume":"12","author":"X Wu","year":"2024","unstructured":"Wu, X. et al. Single-cell sequencing to multi-omics: technologies and applications. Biomark. Res. 12, 110 (2024).","journal-title":"Biomark. Res."},{"key":"2850_CR69","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41568-022-00486-x","volume":"22","author":"RC Gimple","year":"2022","unstructured":"Gimple, R. C. et al. Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. Nat. Rev. Cancer. 22, 497\u2013514 (2022).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR70","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eururo.2016.06.025","volume":"71","author":"Z Yang","year":"2017","unstructured":"Yang, Z. et al. Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells. Eur. Urol. 71, 8\u201312 (2017).","journal-title":"Eur. Urol."},{"key":"2850_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26271-2","volume":"12","author":"A Andersson","year":"2021","unstructured":"Andersson, A. et al. Spatial deconvolution of HER2-positive breast cancer delineates tumor- associated cell type interactions. Nat. Commun. 12, 6012 (2021).","journal-title":"Nat. Commun."},{"key":"2850_CR72","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.7150\/ijbs.43887","volume":"16","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Encoding method of single-cell spatial transcriptomics sequencing. Int. J. Biol. Sci. 16, 2663\u20132674 (2020).","journal-title":"Int. J. Biol. Sci."},{"key":"2850_CR73","doi-asserted-by":"crossref","unstructured":"Method of the Year 2020: spatially resolved transcriptomics. Nat. Methods. 18, 1, (2021).","DOI":"10.1038\/s41592-020-01042-x"},{"key":"2850_CR74","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41586-021-04217-4","volume":"601","author":"T Zhao","year":"2022","unstructured":"Zhao, T. et al. Spatial genomics enables multi-modal study of clonal heterogeneity in tissues. Nature 601, 85\u201391 (2022).","journal-title":"Nature"},{"key":"2850_CR75","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1038\/s41592-024-02438-9","volume":"21","author":"C Ma","year":"2024","unstructured":"Ma, C. et al. Inferring allele-specific copy number aberrations and tumor phylogeography from spatially resolved transcriptomics. Nat. Methods. 21, 2239\u20132247 (2024).","journal-title":"Nat. Methods."},{"key":"2850_CR76","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.cell.2020.08.043","volume":"182","author":"AL Ji","year":"2020","unstructured":"Ji, A. L. et al. Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma. Cell 182, 1661\u20131662 (2020).","journal-title":"Cell"},{"key":"2850_CR77","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41588-022-01268-9","volume":"55","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens. Nat. Genet. 55, 19\u201325 (2023).","journal-title":"Nat. Genet."},{"key":"2850_CR78","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41559-021-01615-9","volume":"6","author":"R Noble","year":"2022","unstructured":"Noble, R. et al. Spatial structure governs the mode of tumour evolution. Nat. Ecol. Evol. 6, 207\u2013217 (2022).","journal-title":"Nat. Ecol. Evol."},{"key":"2850_CR79","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.1133427","volume":"314","author":"T Sj\u00f6blom","year":"2006","unstructured":"Sj\u00f6blom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268\u2013274 (2006).","journal-title":"Science"},{"key":"2850_CR80","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.cell.2022.04.015","volume":"185","author":"D Yang","year":"2022","unstructured":"Yang, D. et al. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell 185, 1905\u20131923 e1925 (2022).","journal-title":"Cell"},{"key":"2850_CR81","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.ccell.2021.05.005","volume":"39","author":"KP Simeonov","year":"2021","unstructured":"Simeonov, K. P. et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39, 1150\u20131162 e1159 (2021).","journal-title":"Cancer Cell"},{"key":"2850_CR82","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","volume":"16","author":"K Pantel","year":"2010","unstructured":"Pantel, K. & Alix-Panabi\u00e8res, C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 16, 398\u2013406 (2010).","journal-title":"Trends Mol Med."},{"key":"2850_CR83","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ccell.2017.01.002","volume":"31","author":"A Bardelli","year":"2017","unstructured":"Bardelli, A. & Pantel, K. Liquid biopsies, what we do not know (Yet). Cancer Cell 31, 172\u2013179 (2017).","journal-title":"Cancer Cell"},{"key":"2850_CR84","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1158\/2159-8290.CD-22-1023","volume":"12","author":"HE Deubzer","year":"2022","unstructured":"Deubzer, H. E., Astrahantseff, K. & Lodrini, M. A deep dive into the circulating ctDNA cosmos to vanquish neuroblastoma. Cancer Discov 12, 2727\u20132729 (2022).","journal-title":"Cancer Discov"},{"key":"2850_CR85","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/2159-8290.CD-22-0287","volume":"12","author":"KR Bosse","year":"2022","unstructured":"Bosse, K. R. et al. Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma. Cancer Discov 12, 2800\u20132819 (2022).","journal-title":"Cancer Discov"},{"key":"2850_CR86","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","volume":"86","author":"I Nordentoft","year":"2024","unstructured":"Nordentoft, I. et al. Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma. Eur. Urol. 86, 301\u2013311 (2024).","journal-title":"Eur. Urol."},{"key":"2850_CR87","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","volume":"26","author":"A Zviran","year":"2020","unstructured":"Zviran, A. et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat. Med. 26, 1114\u20131124 (2020).","journal-title":"Nat. Med."},{"key":"2850_CR88","first-page":"2025","volume":"189250","author":"CB Avci","year":"1880","unstructured":"Avci, C. B. et al. Precision oncology: using cancer genomics for targeted therapy advancements. Biochim. Biophys. Acta Rev. Cancer. 189250, 2025 (1880).","journal-title":"Biochim. Biophys. Acta Rev. Cancer."},{"key":"2850_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23912-4","volume":"12","author":"KE Poels","year":"2021","unstructured":"Poels, K. E. et al. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I\/II trial in advanced EGFR-mutant non-small cell lung cancer. Nat. Commun. 12, 3697 (2021).","journal-title":"Nat. Commun."},{"key":"2850_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00854-6","volume":"13","author":"TJ Nicholas","year":"2021","unstructured":"Nicholas, T. J. et al. OncoGEMINI: software for investigating tumor variants from multiple biopsies with integrated cancer annotations. Genome Med 13, 46 (2021).","journal-title":"Genome Med"},{"key":"2850_CR91","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1158\/0008-5472.CAN-21-2318","volume":"82","author":"PH Acosta","year":"2022","unstructured":"Acosta, P. H. et al. Intratumoral resolution of driver gene mutation heterogeneity in renal cancer using deep learning. Cancer Res 82, 2792\u20132806 (2022).","journal-title":"Cancer Res"},{"key":"2850_CR92","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-20-4119","volume":"27","author":"E Marostica","year":"2021","unstructured":"Marostica, E. et al. Development of a histopathology informatics pipeline for classification and prediction of clinical outcomes in subtypes of renal cell carcinoma. Clin. Cancer Res. 27, 2868\u20132878 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2850_CR93","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s41591-018-0177-5","volume":"24","author":"N Coudray","year":"2018","unstructured":"Coudray, N. et al. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat. Med. 24, 1559\u20131567 (2018).","journal-title":"Nat. Med."},{"key":"2850_CR94","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s43018-020-0085-8","volume":"1","author":"Y Fu","year":"2020","unstructured":"Fu, Y. et al. Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis. Nat. Cancer. 1, 800\u2013810 (2020).","journal-title":"Nat. Cancer."},{"key":"2850_CR95","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s43018-020-0087-6","volume":"1","author":"JN Kather","year":"2020","unstructured":"Kather, J. N. et al. Pan-cancer image-based detection of clinically actionable genetic alterations. Nat. Cancer 1, 789\u2013799 (2020).","journal-title":"Nat. Cancer"},{"key":"2850_CR96","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/nm.3915","volume":"21","author":"AA Alizadeh","year":"2015","unstructured":"Alizadeh, A. A. et al. Toward understanding and exploiting tumor heterogeneity. Nat. Med. 21, 846\u2013853 (2015).","journal-title":"Nat. Med."},{"key":"2850_CR97","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.tibtech.2021.11.006","volume":"40","author":"A Kashyap","year":"2022","unstructured":"Kashyap, A. et al. Quantification of tumor heterogeneity: from data acquisition to metric generation. Trends Biotechnol 40, 647\u2013676 (2022).","journal-title":"Trends Biotechnol"},{"key":"2850_CR98","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc3971","volume":"15","author":"DP Tabassum","year":"2015","unstructured":"Tabassum, D. P. & Polyak, K. Tumorigenesis: it takes a village. Nat. Rev. Cancer 15, 473\u2013483 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"2850_CR99","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/2159-8290.CD-17-0891","volume":"8","author":"KH Khan","year":"2018","unstructured":"Khan, K. H. et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov 8, 1270\u20131285 (2018).","journal-title":"Cancer Discov"},{"key":"2850_CR100","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41568-023-00610-5","volume":"23","author":"M Alieva","year":"2023","unstructured":"Alieva, M., Wezenaar, A. A.-O., Wehrens, E. J. & Rios, A. A.-O. Bridging live-cell imaging and next-generation cancer treatment. Nat. Rev. Cancer. 23, 731\u2013745 (2023).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR101","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41556-018-0109-0","volume":"20","author":"MA-O Reeves","year":"2018","unstructured":"Reeves, M. A.-O. et al. Multicolour lineage tracing reveals clonal dynamics of squamous carcinoma evolution from initiation to metastasis. Nat. Cell Biol. 20, 699\u2013709 (2018).","journal-title":"Nat. Cell Biol."},{"key":"2850_CR102","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41586-022-05242-7","volume":"610","author":"P Karras","year":"2022","unstructured":"Karras, P. et al. A cellular hierarchy in melanoma uncouples growth and metastasis. Nature 610, 190\u2013198 (2022).","journal-title":"Nature"},{"key":"2850_CR103","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.19.03077","volume":"38","author":"A Makiyama","year":"2020","unstructured":"Makiyama, A. et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J. Clin. Oncol. 38, 1919\u20131927 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2850_CR104","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-019-0737-2","volume":"12","author":"D Zhao","year":"2019","unstructured":"Zhao, D., Klempner, S. J. & Chao, J. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. J. Hematol. Oncol. 12, 50 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2850_CR105","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-17-0787","volume":"8","author":"YY Janjigian","year":"2018","unstructured":"Janjigian, Y. Y. et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov 8, 49\u201358 (2018).","journal-title":"Cancer Discov"},{"key":"2850_CR106","doi-asserted-by":"publisher","first-page":"s33","DOI":"10.7861\/clinmedicine.14-6-s33","volume":"14","author":"CT Hiley","year":"2014","unstructured":"Hiley, C. T. & Swanton, C. Spatial and temporal cancer evolution: causes and consequences of tumour diversity. Clin. Med. 14, s33\u2013s37 (2014).","journal-title":"Clin. Med."},{"key":"2850_CR107","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/2159-8290.CD-20-1285","volume":"11","author":"AA-OX Sinjab","year":"2021","unstructured":"Sinjab, A. A.-O. X. et al. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov 11, 2506\u20132523 (2021).","journal-title":"Cancer Discov"},{"key":"2850_CR108","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.ccell.2022.11.001","volume":"40","author":"R Li","year":"2022","unstructured":"Li, R. et al. Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. Cancer Cell 40, 1583\u20131599.e1510 (2022).","journal-title":"Cancer Cell"},{"key":"2850_CR109","doi-asserted-by":"publisher","first-page":"188782","DOI":"10.1016\/j.bbcan.2022.188782","volume":"1877","author":"X Lou","year":"2022","unstructured":"Lou, X. et al. Spatiotemporal heterogeneity and clinical challenge of pancreatic neuroendocrine tumors. Biochim. Biophys. Acta Rev. Cancer 1877, 188782 (2022).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2850_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22115-0","volume":"8","author":"D Walter","year":"2018","unstructured":"Walter, D. et al. Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors. Sci. Rep. 8, 3811 (2018).","journal-title":"Sci. Rep."},{"key":"2850_CR111","doi-asserted-by":"publisher","first-page":"17498","DOI":"10.3748\/wjg.v20.i46.17498","volume":"20","author":"N Gebauer","year":"2014","unstructured":"Gebauer, N. Genomic landscape of pancreatic neuroendocrine tumors. World J. Gastroenterol 20, 17498 (2014).","journal-title":"World J. Gastroenterol"},{"key":"2850_CR112","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ng.2891","volume":"46","author":"M Gerlinger","year":"2014","unstructured":"Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225\u2013233 (2014).","journal-title":"Nat. Genet."},{"key":"2850_CR113","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/ng.3641","volume":"48","author":"R Gao","year":"2016","unstructured":"Gao, R. et al. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat. Genet. 48, 1119\u20131130 (2016).","journal-title":"Nat. Genet."},{"key":"2850_CR114","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","volume":"61","author":"ER Fearon","year":"1990","unstructured":"Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759\u2013767 (1990).","journal-title":"Cell"},{"key":"2850_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-15-35","volume":"15","author":"W Jiao","year":"2014","unstructured":"Jiao, W. et al. Inferring clonal evolution of tumors from single nucleotide somatic mutations. BMC Bioinformatics 15, 35 (2014).","journal-title":"BMC Bioinformatics"},{"key":"2850_CR116","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature13600","volume":"512","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155\u2013160 (2014).","journal-title":"Nature"},{"key":"2850_CR117","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.18632\/oncotarget.3111","volume":"6","author":"AB Kr\u00f8ig\u00e5rd","year":"2015","unstructured":"Kr\u00f8ig\u00e5rd, A. B. et al. Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis. Oncotarget. 6, 5634\u20135649 (2015).","journal-title":"Oncotarget."},{"key":"2850_CR118","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506\u2013510 (2012).","journal-title":"Nature"},{"key":"2850_CR119","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1182\/blood-2012-05-433540","volume":"120","author":"A Schuh","year":"2012","unstructured":"Schuh, A. et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 120, 4191\u20134196 (2012).","journal-title":"Blood"},{"key":"2850_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0433-z","volume":"15","author":"R Fisher","year":"2014","unstructured":"Fisher, R. et al. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biol. 15, 433 (2014).","journal-title":"Genome Biol."},{"key":"2850_CR121","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature13600","volume":"512","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Clonal evolution in breast cancer revealed by single-nucleus genome sequencing. Nature 512, 155\u2013160 (2014).","journal-title":"Nature"},{"key":"2850_CR122","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/cr.2014.43","volume":"24","author":"C Yu","year":"2014","unstructured":"Yu, C. et al. Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. Cell Res 24, 701\u2013712 (2014).","journal-title":"Cell Res"},{"key":"2850_CR123","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2012.02.028","volume":"148","author":"Y Hou","year":"2012","unstructured":"Hou, Y. et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148, 873\u2013885 (2012).","journal-title":"Cell"},{"key":"2850_CR124","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994\u20131007 (2012).","journal-title":"Cell"},{"key":"2850_CR125","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature10933","volume":"486","author":"SP Shah","year":"2012","unstructured":"Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395\u2013399 (2012).","journal-title":"Nature"},{"key":"2850_CR126","doi-asserted-by":"publisher","first-page":"13081","DOI":"10.1073\/pnas.0801523105","volume":"105","author":"PJ Campbell","year":"2008","unstructured":"Campbell, P. J. et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc. Natl. Acad. Sci. USA 105, 13081\u201313086 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR127","doi-asserted-by":"publisher","first-page":"17947","DOI":"10.1073\/pnas.1420822111","volume":"111","author":"C Gawad","year":"2014","unstructured":"Gawad, C., Koh, W. & Quake, S. R. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc. Natl. Acad. Sci. USA 111, 17947\u201317952 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR128","doi-asserted-by":"publisher","first-page":"E6496","DOI":"10.1073\/pnas.1519556112","volume":"112","author":"S Ling","year":"2015","unstructured":"Ling, S. et al. Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc. Natl. Acad. Sci. USA 112, E6496\u2013E6505 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR129","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ng.3214","volume":"47","author":"A Sottoriva","year":"2015","unstructured":"Sottoriva, A. et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47, 209\u2013216 (2015).","journal-title":"Nat. Genet."},{"key":"2850_CR130","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1158\/1078-0432.CCR-14-2413","volume":"21","author":"T-M Kim","year":"2015","unstructured":"Kim, T.-M. et al. Subclonal genomic architectures of primary and metastatic colorectal cancer based on intratumoral genetic heterogeneity. Clin. Cancer Res. 21, 4461\u20134472 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2850_CR131","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/ng.3573","volume":"48","author":"A McPherson","year":"2016","unstructured":"McPherson, A. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758\u2013767 (2016).","journal-title":"Nat. Genet."},{"key":"2850_CR132","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/ng.3315","volume":"47","author":"PC Boutros","year":"2015","unstructured":"Boutros, P. C. et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47, 736\u2013745 (2015).","journal-title":"Nat. Genet."},{"key":"2850_CR133","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1158\/0008-5472.CAN-15-3476","volume":"76","author":"K Harbst","year":"2016","unstructured":"Harbst, K. et al. Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma. Cancer Res 76, 4765\u20134774 (2016).","journal-title":"Cancer Res"},{"key":"2850_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-015-0269-0","volume":"4","author":"LM Hoffman","year":"2016","unstructured":"Hoffman, L. M. et al. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol. Commun. 4, 1 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"2850_CR135","doi-asserted-by":"publisher","first-page":"12094","DOI":"10.18632\/oncotarget.3297","volume":"6","author":"M Aubry","year":"2015","unstructured":"Aubry, M. et al. From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity. Oncotarget 6, 12094\u201312109 (2015).","journal-title":"Oncotarget"},{"key":"2850_CR136","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1073\/pnas.1219747110","volume":"110","author":"A Sottoriva","year":"2013","unstructured":"Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA 110, 4009\u20134014 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR137","doi-asserted-by":"crossref","unstructured":"Venkatesan, S. & Swanton, C. Tumor evolutionary principles: how intratumor heterogeneity influences cancer treatment and outcome. Am. Soc. Clin. Oncol. Educ. Book (2016).","DOI":"10.1200\/EDBK_158930"},{"key":"2850_CR138","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature13948","volume":"518","author":"D Juric","year":"2015","unstructured":"Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor. Nature 518, 240\u2013244 (2015).","journal-title":"Nature"},{"key":"2850_CR139","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/ng.3489","volume":"48","author":"MJ Williams","year":"2016","unstructured":"Williams, M. J. et al. Identification of neutral tumor evolution across cancer types. Nat. Genet. 48, 238\u2013244 (2016).","journal-title":"Nat. Genet."},{"key":"2850_CR140","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/blood-2016-11-750612","volume":"130","author":"DC Johnson","year":"2017","unstructured":"Johnson, D. C. et al. Neutral tumor evolution in myeloma is associated with poor prognosis. Blood 130, 1639\u20131643 (2017).","journal-title":"Blood"},{"key":"2850_CR141","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1182\/blood.2020008407","volume":"137","author":"A-M Lyne","year":"2021","unstructured":"Lyne, A.-M., Laplane, L. & Peri\u00e9, L. To portray clonal evolution in blood cancer, count your stem cells. Blood 137, 1862\u20131870 (2021).","journal-title":"Blood"},{"key":"2850_CR142","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/366223a0","volume":"366","author":"SJ Gould","year":"1993","unstructured":"Gould, S. J. & Eldredge, N. Punctuated equilibrium comes of age. Nature 366, 223\u2013227 (1993).","journal-title":"Nature"},{"key":"2850_CR143","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","volume":"153","author":"S Baca","year":"2013","unstructured":"Baca, S. & Ylvan, C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666\u2013677 (2013).","journal-title":"Cell"},{"key":"2850_CR144","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"2850_CR145","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41588-021-00891-2","volume":"53","author":"Y Bollen","year":"2021","unstructured":"Bollen, Y. et al. Reconstructing single-cell karyotype alterations in colorectal cancer identifies punctuated and gradual diversification patterns. Nat. Genet. 53, 1187\u20131195 (2021).","journal-title":"Nat. Genet."},{"key":"2850_CR146","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","volume":"144","author":"PJ Stephens","year":"2011","unstructured":"Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27\u201340 (2011).","journal-title":"Cell"},{"key":"2850_CR147","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/sj.bjc.6605912","volume":"103","author":"M Gerlinger","year":"2010","unstructured":"Gerlinger, M. & Swanton, C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 103, 1139\u20131143 (2010).","journal-title":"Br. J. Cancer"},{"key":"2850_CR148","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2011.12.013","volume":"148","author":"T Rausch","year":"2012","unstructured":"Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59\u201371 (2012).","journal-title":"Cell"},{"key":"2850_CR149","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/35094059","volume":"1","author":"MJ Bissell","year":"2001","unstructured":"Bissell, M. J. & Radisky, D. Putting tumours in context. Nat. Rev. Cancer. 1, 46\u201354 (2001).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR150","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41586-022-05311-x","volume":"611","author":"J Househam","year":"2022","unstructured":"Househam, J. et al. Phenotypic plasticity and genetic control in colorectal cancer evolution. Nature 611, 744\u2013753 (2022).","journal-title":"Nature"},{"key":"2850_CR151","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1073\/pnas.73.2.549","volume":"73","author":"K Illmensee","year":"1976","unstructured":"Illmensee, K. & Mintz, B. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc. Natl. Acad. Sci. USA 73, 549\u2013553 (1976).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR152","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1073\/pnas.72.9.3585","volume":"72","author":"B Mintz","year":"1975","unstructured":"Mintz, B. & Illmensee, K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. USA 72, 3585\u20133589 (1975).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR153","doi-asserted-by":"publisher","first-page":"eaaw3835","DOI":"10.1126\/science.aaw3835","volume":"379","author":"AP Feinberg","year":"2023","unstructured":"Feinberg, A. P. & Levchenko, A. Epigenetics as a mediator of plasticity in cancer. Science 379, eaaw3835 (2023).","journal-title":"Science"},{"key":"2850_CR154","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","volume":"183","author":"S Shen","year":"2020","unstructured":"Shen, S., Vagner, S. & Robert, C. Persistent cancer cells: the deadly survivors. Cell 183, 860\u2013874 (2020).","journal-title":"Cell"},{"key":"2850_CR155","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"J-C Marine","year":"2020","unstructured":"Marine, J.-C., Dawson, S.-J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743\u2013756 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2850_CR156","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi, S. & Sauvage, F. J. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19, 39\u201356 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2850_CR157","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41568-024-00757-9","volume":"25","author":"M Laisn\u00e9","year":"2025","unstructured":"Laisn\u00e9, M., Lupien, M. & Vallot, C. Epigenomic heterogeneity as a source of tumour evolution. Nat. Rev. Cancer. 25, 7\u201326 (2025).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR158","doi-asserted-by":"publisher","first-page":"015002","DOI":"10.1088\/1478-3975\/8\/1\/015002","volume":"8","author":"J Foo","year":"2011","unstructured":"Foo, J., Leder, K. & Michor, F. Stochastic dynamics of cancer initiation. Phys. Biol. 8, 015002 (2011).","journal-title":"Phys. Biol."},{"key":"2850_CR159","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","volume":"187","author":"R Mathur","year":"2024","unstructured":"Mathur, R. et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell 187, 446\u2013463.e416 (2024).","journal-title":"Cell"},{"key":"2850_CR160","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature19823","volume":"538","author":"F Notta","year":"2016","unstructured":"Notta, F. et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538, 378\u2013382 (2016).","journal-title":"Nature"},{"key":"2850_CR161","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s43018-023-00584-1","volume":"4","author":"L Perelli","year":"2023","unstructured":"Perelli, L. et al. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat. Cancer 4, 984\u20131000 (2023).","journal-title":"Nat. Cancer"},{"key":"2850_CR162","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","volume":"18","author":"NJ Choudhury","year":"2023","unstructured":"Choudhury, N. J. et al. Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancer s. J. Thorac. Oncol. 18, 463\u2013475 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2850_CR163","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/0008-5472.CAN-22-2912","volume":"83","author":"W Liu","year":"2023","unstructured":"Liu, W. et al. The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer. Cancer Res 83, 506\u2013520 (2023).","journal-title":"Cancer Res"},{"key":"2850_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00963-0","volume":"8","author":"P Ma","year":"2017","unstructured":"Ma, P. et al. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat. Commun. 8, 823 (2017).","journal-title":"Nat. Commun."},{"key":"2850_CR165","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1253462","volume":"346","author":"EC de Bruin","year":"2014","unstructured":"de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251\u2013256 (2014).","journal-title":"Science"},{"key":"2850_CR166","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-023-01425-5","volume":"16","author":"K Butler","year":"2023","unstructured":"Butler, K. & Banday, A. R. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential. J. Hematol. Oncol. 16, 31 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2850_CR167","unstructured":"Lv, W. et al. Spatial-temporal diversity of extrachromosomal DNA shapes urothelial carcinoma evolution and tumor-immune microenvironment. Cancer Discov. CD-24-1532 (2025)."},{"key":"2850_CR168","doi-asserted-by":"publisher","first-page":"e12191","DOI":"10.1016\/j.heliyon.2022.e12191","volume":"8","author":"T Peng","year":"2022","unstructured":"Peng, T. et al. APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma. Heliyon 8, e12191 (2022).","journal-title":"Heliyon"},{"key":"2850_CR169","doi-asserted-by":"publisher","first-page":"998653","DOI":"10.3389\/fimmu.2022.998653","volume":"13","author":"J Ren","year":"2022","unstructured":"Ren, J. et al. Comprehensive characterisation of immunogenic cell death in melanoma revealing the association with prognosis and tumor immune microenvironment. Front. Immunol 13, 998653 (2022).","journal-title":"Front. Immunol"},{"key":"2850_CR170","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41588-025-02187-1","volume":"57","author":"AA-O Gupta","year":"2025","unstructured":"Gupta, A. A.-O. et al. APOBEC3 mutagenesis drives therapy resistance in breast cancer. Nat. Genet. 57, 1452\u20131462 (2025).","journal-title":"Nat. Genet."},{"key":"2850_CR171","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41422-024-01054-8","volume":"35","author":"Q-L Yang","year":"2025","unstructured":"Yang, Q.-L. et al. Modern biology of extrachromosomal DNA: A decade-long voyage of discovery. Cell Res 35, 11\u201322 (2025).","journal-title":"Cell Res"},{"key":"2850_CR172","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev-pathmechdis-051821-114223","volume":"17","author":"S Wu","year":"2022","unstructured":"Wu, S., Bafna, V., Chang, H. Y. & Mischel, P. S. Extrachromosomal DNA: an emerging hallmark in human cancer. Annu. Rev. Pathol. 17, 367\u2013386 (2022).","journal-title":"Annu. Rev. Pathol."},{"key":"2850_CR173","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2019.10.039","volume":"179","author":"AR Morton","year":"2019","unstructured":"Morton, A. R. et al. Functional enhancers shape extrachromosomal oncogene amplifications. Cell 179, 1330\u20131341.e1313 (2019).","journal-title":"Cell"},{"key":"2850_CR174","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1242\/jcs.114.1.49","volume":"114","author":"T Kanda","year":"2001","unstructured":"Kanda, T., Otter, M. & Wahl, G. M. Mitotic segregation of viral and cellular acentric extrachromosomal molecules by chromosome tethering. J. Cell Sci. 114, 49\u201358 (2001).","journal-title":"J. Cell Sci."},{"key":"2850_CR175","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nature21356","volume":"543","author":"KM Turner","year":"2017","unstructured":"Turner, K. M. et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543, 122\u2013125 (2017).","journal-title":"Nature"},{"key":"2850_CR176","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41588-022-01177-x","volume":"54","author":"JA-O Lange","year":"2022","unstructured":"Lange, J. A.-O. et al. The evolutionary dynamics of extrachromosomal DNA in human cancers. Nat. Genet. 54, 1527\u20131533 (2022).","journal-title":"Nat. Genet."},{"key":"2850_CR177","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41576-019-0114-6","volume":"20","author":"S Turajlic","year":"2019","unstructured":"Turajlic, S., Sottoriva, A., Graham, T. & Swanton, C. Resolving genetic heterogeneity in cancer. Nat. Rev. Genet. 20, 404\u2013416 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"2850_CR178","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41588-023-01386-y","volume":"55","author":"R Chamorro Gonz\u00e1lez","year":"2023","unstructured":"Chamorro Gonz\u00e1lez, R. et al. Parallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells. Nat. Genet. 55, 880\u2013890 (2023).","journal-title":"Nat. Genet."},{"key":"2850_CR179","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41586-023-05937-5","volume":"616","author":"J Luebeck","year":"2023","unstructured":"Luebeck, J. et al. Extrachromosomal DNA in the cancerous transformation of Barrett\u2019s oesophagus. Nature 616, 798\u2013805 (2023).","journal-title":"Nature"},{"key":"2850_CR180","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41588-019-0547-z","volume":"52","author":"RP Koche","year":"2020","unstructured":"Koche, R. P. et al. Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. Nat. Genet. 52, 29\u201334 (2020).","journal-title":"Nat. Genet."},{"key":"2850_CR181","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41586-022-04398-6","volume":"602","author":"EN Bergstrom","year":"2022","unstructured":"Bergstrom, E. N. et al. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of e cDNA. Nature 602, 510\u2013517 (2022).","journal-title":"Nature"},{"key":"2850_CR182","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41586-020-03064-z","volume":"591","author":"O Shoshani","year":"2021","unstructured":"Shoshani, O. et al. Chromothripsis drives the evolution of gene amplification in cancer. Nature 591, 137\u2013141 (2021).","journal-title":"Nature"},{"key":"2850_CR183","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1038\/s41588-021-00951-7","volume":"53","author":"C Rosswog","year":"2021","unstructured":"Rosswog, C. et al. Chromothripsis followed by circular recombination drives oncogene amplification in human cancer. Nat. Genet. 53, 1673\u20131685 (2021).","journal-title":"Nat. Genet."},{"key":"2850_CR184","first-page":"1171","volume":"7","author":"E Raymond","year":"2001","unstructured":"Raymond, E. et al. Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas. Clin Cancer Res 7, 1171\u20131180 (2001).","journal-title":"Clin Cancer Res"},{"key":"2850_CR185","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41586-021-04116-8","volume":"600","author":"KL Hung","year":"2021","unstructured":"Hung, K. L. et al. ecDNA hubs drive cooperative intermolecular oncogene expression. Nature 600, 731\u2013736 (2021).","journal-title":"Nature"},{"key":"2850_CR186","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2159-8290.CD-21-1376","volume":"12","author":"E Yi","year":"2022","unstructured":"Yi, E. et al. Live-cell imaging shows uneven segregation of extrachromosomal DNA elements and transcriptionally active extrachromosomal DNA hubs in cancer. Cancer Discov 12, 468\u2013483 (2022).","journal-title":"Cancer Discov"},{"key":"2850_CR187","doi-asserted-by":"publisher","first-page":"103477","DOI":"10.1016\/j.critrevonc.2021.103477","volume":"166","author":"M Karami Fath","year":"2021","unstructured":"Karami Fath, M. et al. Extra chromosomal DNA in different cancers: individual genome with important biological functions. Crit. Rev. Oncol. Hematol. 166, 103477 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2850_CR188","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/s41591-023-02230-w","volume":"29","author":"T Karasaki","year":"2023","unstructured":"Karasaki, T. et al. Evolutionary characterisation of lung adenocarcinoma morphology in TRA CERx. Nat. Med. 29, 833\u2013845 (2023).","journal-title":"Nat. Med."},{"key":"2850_CR189","doi-asserted-by":"publisher","first-page":"a028373","DOI":"10.1101\/cshperspect.a028373","volume":"7","author":"L Sansregret","year":"2017","unstructured":"Sansregret, L. & Swanton, C. The role of aneuploidy in cancer evolution. Cold Spring Harb. Perspect. Med. 7, a028373 (2017).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2850_CR190","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trecan.2021.09.002","volume":"8","author":"DA Lukow","year":"2022","unstructured":"Lukow, D. A. & Sheltzer, J. M. Chromosomal instability and aneuploidy as causes of cancer drug resistance. Trends Cancer 8, 43\u201353 (2022).","journal-title":"Trends Cancer"},{"key":"2850_CR191","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41588-019-0399-6","volume":"51","author":"ACF Bolhaqueiro","year":"2019","unstructured":"Bolhaqueiro, A. C. F. et al. Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids. Nat Genet 51, 824\u2013834 (2019).","journal-title":"Nat Genet"},{"key":"2850_CR192","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.3390\/ijms26083826","volume":"26","author":"F Pellestor","year":"2025","unstructured":"Pellestor, F., Ganne, B., Gaillard, J. B. & Gatinois, V. Chromoplexy: a pathway to genomic complexity and cancer development. Int. J. Mol. Sci. 26, 3826 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"2850_CR193","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.semcdb.2021.03.003","volume":"123","author":"R Dahiya","year":"2022","unstructured":"Dahiya, R., Hu, Q. & Ly, P. Mechanistic origins of diverse genome rearrangements in cancer. Semin. Cell Dev. Biol. 123, 100\u2013109 (2022).","journal-title":"Semin. Cell Dev. Biol."},{"key":"2850_CR194","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.semcdb.2021.01.004","volume":"123","author":"F Pellestor","year":"2022","unstructured":"Pellestor, F. et al. Chromoanagenesis, the mechanisms of a genomic chaos. Semin. Cell Dev. Biol. 123, 90\u201399 (2022).","journal-title":"Semin. Cell Dev. Biol."},{"key":"2850_CR195","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13039-022-00600-6","volume":"15","author":"B Burssed","year":"2022","unstructured":"Burssed, B., Zamariolli, M., Bellucco, F. T. & Melaragno, M. I. Mechanisms of structural chromosomal rearrangement formation. Mol. Cytogenet. 15, 23 (2022).","journal-title":"Mol. Cytogenet."},{"key":"2850_CR196","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"SA Tomlins","year":"2005","unstructured":"Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644\u2013648 (2005).","journal-title":"Science"},{"key":"2850_CR197","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1158\/0008-5472.CAN-20-1920","volume":"80","author":"M Bolkestein","year":"2020","unstructured":"Bolkestein, M. et al. Chromothripsis in human breast cancer. Cancer Res 80, 4918\u20134931 (2020).","journal-title":"Cancer Res"},{"key":"2850_CR198","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1101\/gr.151670.112","volume":"23","author":"DE Newburger","year":"2013","unstructured":"Newburger, D. E. et al. Genome evolution during progression to breast cancer. Genome Res 23, 1097\u20131108 (2013).","journal-title":"Genome Res"},{"key":"2850_CR199","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nrc3063","volume":"11","author":"LA Loeb","year":"2011","unstructured":"Loeb, L. A. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer. 11, 450\u2013457 (2011).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR200","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/em.20111","volume":"45","author":"JH Bielas","year":"2005","unstructured":"Bielas, J. H. & Loeb, L. A. Mutator phenotype in cancer: timing and perspectives. Environ. Mol. Mutagen. 45, 206\u2013213 (2005).","journal-title":"Environ. Mol. Mutagen."},{"key":"2850_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.10","volume":"49","author":"M Kim","year":"2017","unstructured":"Kim, M. & Costello, J. DNA methylation: an epigenetic mark of cellular memory. Exp. Mol. Med. 49, e322 (2017).","journal-title":"Exp. Mol. Med."},{"key":"2850_CR202","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/pcmr.12745","volume":"32","author":"GA-O Micevic","year":"2019","unstructured":"Micevic, G. A.-O., Thakral, D., McGeary, M. & Bosenberg, M. W. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival. Pigment Cell Melanoma Res 32, 435\u2013440 (2019).","journal-title":"Pigment Cell Melanoma Res"},{"key":"2850_CR203","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41591-018-0091-x","volume":"24","author":"DK Patten","year":"2018","unstructured":"Patten, D. K. et al. Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nat. Med. 24, 1469\u20131480 (2018).","journal-title":"Nat. Med."},{"key":"2850_CR204","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nsmb.3153","volume":"23","author":"E Metzger","year":"2016","unstructured":"Metzger, E. et al. Assembly of methylated KDM1A and CHD1 drives androgen receptor\u2013dependent transcription and translocation. Nat. Struct. Mol. Biol. 23, 132\u2013139 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2850_CR205","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/biom14070747","volume":"14","author":"G Oliviero","year":"2024","unstructured":"Oliviero, G. et al. Expression Proteomics and Histone Analysis Reveal Extensive Chromatin Network Changes and a Role for Histone Tail Trimming during Cellular Differentiation. Biomolecules 14, 747 (2024).","journal-title":"Biomolecules"},{"key":"2850_CR206","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat Med. 22, 128\u2013134 (2016).","journal-title":"Nat Med."},{"key":"2850_CR207","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/2159-8290.CD-23-1161","volume":"14","author":"D Rosano","year":"2024","unstructured":"Rosano, D. et al. Long-term multimodal recording reveals epigenetic adaptation routes in dormant breast cancer cells. Cancer Discov 14, 866\u2013889 (2024).","journal-title":"Cancer Discov"},{"key":"2850_CR208","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41588-024-01920-6","volume":"56","author":"JS Schiffman","year":"2024","unstructured":"Schiffman, J. S. et al. Defining heritability, plasticity, and transition dynamics of cellular phenotypes in somatic evolution. Nat. Genet. 56, 2174\u20132184 (2024).","journal-title":"Nat. Genet."},{"key":"2850_CR209","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/2159-8290.CD-19-0015","volume":"9","author":"S Yuan","year":"2019","unstructured":"Yuan, S., Norgard, R. J. & Stanger, B. Z. Cellular plasticity in cancer. Cancer Discov 9, 837\u2013851 (2019).","journal-title":"Cancer Discov"},{"key":"2850_CR210","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2159-8290.CD-23-0530","volume":"14","author":"G Ciriello","year":"2024","unstructured":"Ciriello, G. et al. Cancer evolution: a multifaceted affair. Cancer Discov 14, 36\u201348 (2024).","journal-title":"Cancer Discov"},{"key":"2850_CR211","doi-asserted-by":"crossref","unstructured":"Lv, J. et al. Epigenetic modification of CSDE1 locus dictates immune recognition of nascent tumorigenic cells. Sci. Transl. Med. 15, eabq6024 (2023).","DOI":"10.1126\/scitranslmed.abq6024"},{"key":"2850_CR212","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","volume":"11","author":"WH Koppenol","year":"2011","unstructured":"Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg\u2019s contributions to current concepts of cancer metabolism. Nat. Rev. Cancer. 11, 325\u2013337 (2011).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR213","doi-asserted-by":"publisher","first-page":"914","DOI":"10.15252\/msb.20167159","volume":"13","author":"NA Graham","year":"2017","unstructured":"Graham, N. A. et al. Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol. Syst. Biol. 13, 914 (2017).","journal-title":"Mol. Syst. Biol."},{"key":"2850_CR214","doi-asserted-by":"publisher","first-page":"e2011342118","DOI":"10.1073\/pnas.2011342118","volume":"118","author":"M Damaghi","year":"2021","unstructured":"Damaghi, M. et al. The harsh microenvironment in early breast cancer selects for a Warburg phenotype. Proc. Natl. Acad. Sci. USA 118, e2011342118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR215","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden, M. G. et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029\u20131033 (2009).","journal-title":"Science"},{"key":"2850_CR216","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1002\/cam4.1820","volume":"7","author":"Y Feng","year":"2018","unstructured":"Feng, Y. et al. Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 7, 6124\u20136136 (2018).","journal-title":"Cancer Med."},{"key":"2850_CR217","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj, G. & Manning, B. D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 20, 74\u201388 (2020).","journal-title":"Nat Rev Cancer"},{"key":"2850_CR218","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05517-9","volume":"22","author":"C Papulino","year":"2024","unstructured":"Papulino, C. et al. Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer. J. Transl. Med. 22, 676 (2024).","journal-title":"J. Transl. Med."},{"key":"2850_CR219","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez, J. A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7, 763\u2013777 (2007).","journal-title":"Nat Rev Cancer"},{"key":"2850_CR220","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros, N. & Poulogiannis, G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer 122, 4\u201322 (2020).","journal-title":"Br J Cancer"},{"key":"2850_CR221","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.apsb.2022.10.021","volume":"13","author":"Q Feng","year":"2023","unstructured":"Feng, Q. et al. A metabolic intervention strategy to break evolutionary adaptability of tumor for reinforced immunotherapy. Acta Pharm. Sin. B 13, 775\u2013786 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"2850_CR222","doi-asserted-by":"publisher","first-page":"2300945","DOI":"10.1002\/smtd.202300945","volume":"8","author":"Y Xie","year":"2024","unstructured":"Xie, Y. et al. Photothermal-enhanced dual inhibition of lactate\/kynurenine metabolism for promoting tumor immunotherapy. Small Methods 8, 2300945 (2024).","journal-title":"Small Methods"},{"key":"2850_CR223","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/neuonc\/nox100","volume":"19","author":"A Prabhu","year":"2017","unstructured":"Prabhu, A. et al. Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis. Neuro Oncol 19, 1599\u20131606 (2017).","journal-title":"Neuro Oncol"},{"key":"2850_CR224","doi-asserted-by":"publisher","first-page":"a026583","DOI":"10.1101\/cshperspect.a026583","volume":"6","author":"Y Yuan","year":"2016","unstructured":"Yuan, Y. Spatial heterogeneity in the tumor microenvironment. Cold Spring Harb. Perspect. Med. 6, a026583 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2850_CR225","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE De Visser","year":"2023","unstructured":"De Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"2850_CR226","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","volume":"36","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell 36, 418\u2013430.e416 (2019).","journal-title":"Cancer Cell"},{"key":"2850_CR227","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1128\/MCB.01121-10","volume":"31","author":"Y Lu","year":"2011","unstructured":"Lu, Y., Chu, A., Turker, M. S. & Glazer, P. M. Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol. Cell. Biol. 31, 3339\u20133350 (2011).","journal-title":"Mol. Cell. Biol."},{"key":"2850_CR228","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccr.2009.12.041","volume":"17","author":"N Erez","year":"2010","unstructured":"Erez, N. et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17, 135\u2013147 (2010).","journal-title":"Cancer Cell"},{"key":"2850_CR229","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.semcdb.2009.10.010","volume":"21","author":"OE Franco","year":"2010","unstructured":"Franco, O. E., Shaw, A. K., Strand, D. W. & Hayward, S. W. Cancer-associated fibroblasts in cancer pathogenesis. Semin. Cell Dev. Biol. 21, 33\u201339 (2010).","journal-title":"Semin. Cell Dev. Biol."},{"key":"2850_CR230","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer. 6, 392\u2013401 (2006).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR231","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-20-4226","volume":"27","author":"PM Galbo","year":"2021","unstructured":"Galbo, P. M., Zang, X. & Zheng, D. Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance. Clin. Cancer Res. 27, 2636\u20132647 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2850_CR232","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137\u2013148 (2004).","journal-title":"Immunity"},{"key":"2850_CR233","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","volume":"7","author":"CR Gil Del Alcazar","year":"2017","unstructured":"Gil Del Alcazar, C. R. et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov 7, 1098\u20131115 (2017).","journal-title":"Cancer Discov"},{"key":"2850_CR234","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ccell.2023.03.019","volume":"41","author":"CE Weeden","year":"2023","unstructured":"Weeden, C. E. et al. Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer Cell 41, 837\u2013852 e836 (2023).","journal-title":"Cancer Cell"},{"key":"2850_CR235","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-020-00292-x","volume":"22","author":"E Armingol","year":"2021","unstructured":"Armingol, E., Officer, A., Harismendy, O. & Lewis, N. E. Deciphering cell\u2013cell interactions and communication from gene expression. Nat. Rev. Genet. 22, 71\u201388 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"2850_CR236","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/cancers12051232","volume":"12","author":"A Dominiak","year":"2020","unstructured":"Dominiak, A., Che\u0142stowska, B., Olejarz, W. & Nowicka, G. Communication in the cancer microenvironment as a target for therapeutic interventions. Cancers 12, 1232 (2020).","journal-title":"Cancers"},{"key":"2850_CR237","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41416-020-01126-7","volume":"124","author":"C Dobie","year":"2021","unstructured":"Dobie, C. & Skropeta, D. Insights into the role of sialylation in cancer progression and metastasis. Br. J. Cancer 124, 76\u201390 (2021).","journal-title":"Br. J. Cancer"},{"key":"2850_CR238","doi-asserted-by":"crossref","unstructured":"Chen G et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, (2018).","DOI":"10.1038\/s41586-018-0392-8"},{"key":"2850_CR239","doi-asserted-by":"crossref","unstructured":"Zhou W et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25, (2014).","DOI":"10.1016\/j.ccr.2014.03.007"},{"key":"2850_CR240","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ncb1725","volume":"10","author":"K Al-Nedawi","year":"2008","unstructured":"Al-Nedawi, K. et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619\u2013624 (2008).","journal-title":"Nat. Cell Biol."},{"key":"2850_CR241","doi-asserted-by":"crossref","unstructured":"Troul\u00e9, K. et al. CellPhoneDB v5: Inferring cell\u2013cell communication from single-cell multiomics data. Nat. Protoc., 1\u201329, (2025).","DOI":"10.1038\/s41596-024-01137-1"},{"key":"2850_CR242","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","volume":"17","author":"R Browaeys","year":"2020","unstructured":"Browaeys, R., Saelens, W. & Saeys, Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat. Methods. 17, 159\u2013162 (2020).","journal-title":"Nat. Methods."},{"key":"2850_CR243","doi-asserted-by":"publisher","first-page":"215823","DOI":"10.1016\/j.canlet.2022.215823","volume":"548","author":"Q Tang","year":"2022","unstructured":"Tang, Q. et al. Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. Cancer Lett 548, 215823 (2022).","journal-title":"Cancer Lett"},{"key":"2850_CR244","doi-asserted-by":"publisher","first-page":"108149","DOI":"10.1016\/j.biotechadv.2023.108149","volume":"66","author":"R Bangarh","year":"2023","unstructured":"Bangarh, R. et al. Aberrant protein glycosylation: Implications on diagnosis and immunotherapy. Biotechnol. Adv. 66, 108149 (2023).","journal-title":"Biotechnol. Adv."},{"key":"2850_CR245","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58\u201362 (2005).","journal-title":"Science"},{"key":"2850_CR246","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd3455","volume":"10","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417\u2013427 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2850_CR247","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrc3298","volume":"12","author":"RJ Gillies","year":"2012","unstructured":"Gillies, R. J., Verduzco, D., Fau-Gatenby, R. A. & Gatenby, R. A. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer. 12, 487\u2013493 (2012).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR248","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41568-018-0030-7","volume":"18","author":"RJ Gillies","year":"2018","unstructured":"Gillies, R. J., Brown, J. S., Anderson, A. R. A. & Gatenby, R. A. Eco-evolutionary causes and consequences of temporal changes in intratumoral blood flow. Nat. Rev. Cancer. 18, 576\u2013585 (2018).","journal-title":"Nat. Rev. Cancer."},{"key":"2850_CR249","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-12-2796","volume":"73","author":"V Estrella","year":"2013","unstructured":"Estrella, V. et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res 73, 1524\u20131535 (2013).","journal-title":"Cancer Res"},{"key":"2850_CR250","first-page":"3847","volume":"63","author":"RA Gatenby","year":"2003","unstructured":"Gatenby, R. A. & Gawlinski, E. T. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 63, 3847\u20133854 (2003).","journal-title":"Cancer Res"},{"key":"2850_CR251","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1152\/physrev.00056.2006","volume":"87","author":"MB Burg","year":"2007","unstructured":"Burg, M. B., Ferraris, J. D. & Dmitrieva, N. I. Cellular response to hyperosmotic stresses. Physiol. Rev. 87, 1441\u20131474 (2007).","journal-title":"Physiol. Rev."},{"key":"2850_CR252","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.aav4474","volume":"366","author":"M Russo","year":"2019","unstructured":"Russo, M. et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science 366, 1473\u20131480 (2019).","journal-title":"Science"},{"key":"2850_CR253","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature12065","volume":"497","author":"M Murtaza","year":"2013","unstructured":"Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108\u2013112 (2013).","journal-title":"Nature"},{"key":"2850_CR254","doi-asserted-by":"publisher","first-page":"10992","DOI":"10.1158\/0008-5472.CAN-05-2612","volume":"65","author":"SJ Isakoff","year":"2005","unstructured":"Isakoff, S. J. et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65, 10992\u201311000 (2005).","journal-title":"Cancer Res"},{"key":"2850_CR255","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01090-2","volume":"14","author":"A Venizelos","year":"2022","unstructured":"Venizelos, A. et al. Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. Genome Med 14, 86 (2022).","journal-title":"Genome Med"},{"key":"2850_CR256","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/S1470-2045(11)70335-7","volume":"13","author":"NC Turner","year":"2012","unstructured":"Turner, N. C. & Reis-Filho, J. S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13, e178\u2013e185 (2012).","journal-title":"Lancet Oncol"},{"key":"2850_CR257","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4802","volume":"5","author":"Y-Z Jiang","year":"2014","unstructured":"Jiang, Y.-Z. et al. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nat. Commun. 5, 3802 (2014).","journal-title":"Nat. Commun."},{"key":"2850_CR258","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-7-229","volume":"9","author":"LA Amos","year":"2008","unstructured":"Amos, L. A. The tektin family of microtubule-stabilizing proteins. Genome Biol 9, 229 (2008).","journal-title":"Genome Biol"},{"key":"2850_CR259","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1016\/j.yexcr.2006.05.014","volume":"312","author":"PW Setter","year":"2006","unstructured":"Setter, P. W. et al. Tektin interactions and a model for molecular functions. Exp. Cell Res. 312, 2880\u20132896 (2006).","journal-title":"Exp. Cell Res."},{"key":"2850_CR260","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"A-M Patch","year":"2015","unstructured":"Patch, A.-M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489\u2013494 (2015).","journal-title":"Nature"},{"key":"2850_CR261","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01174-3","volume":"8","author":"SW Brady","year":"2017","unstructured":"Brady, S. W. et al. Combating subclonal evolution of resistant cancer phenotypes. Nat. Commun. 8, 1231 (2017).","journal-title":"Nat. Commun."},{"key":"2850_CR262","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09312-9","volume":"10","author":"EL Christie","year":"2019","unstructured":"Christie, E. L. et al. Multiple ABCB1 transcriptional fusions in drug-resistant high-grade serous ovarian and breast cancer. Nat. Commun. 10, 1295 (2019).","journal-title":"Nat. Commun."},{"key":"2850_CR263","doi-asserted-by":"crossref","unstructured":"Aldonza, M. B. D. et al. Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms. Sci. Adv. 6, eaav7416 (2020).","DOI":"10.1126\/sciadv.aav7416"},{"key":"2850_CR264","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262\u2013269 (2016).","journal-title":"Nat. Med."},{"key":"2850_CR265","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10690","volume":"7","author":"M Ramirez","year":"2016","unstructured":"Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).","journal-title":"Nat. Commun."},{"key":"2850_CR266","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"2850_CR267","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coisb.2018.03.003","volume":"10","author":"K Kochanowski","year":"2018","unstructured":"Kochanowski, K., Morinishi, L., Altschuler, S. & Wu, L. Drug persistence\u2014from antibiotics to cancer therapies. Curr. Opin. Syst. Biol. 10, 1\u20138 (2018).","journal-title":"Curr. Opin. Syst. Biol."},{"key":"2850_CR268","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0963-7","volume":"17","author":"B Szikriszt","year":"2016","unstructured":"Szikriszt, B. et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol 17, 99 (2016).","journal-title":"Genome Biol"},{"key":"2850_CR269","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","volume":"12","author":"SL Cooke","year":"2011","unstructured":"Cooke, S. L. & Brenton, J. D. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 12, 1169\u20131174 (2011).","journal-title":"Lancet Oncol"},{"key":"2850_CR270","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1158\/0008-5472.CAN-21-0653","volume":"81","author":"H Hirata","year":"2021","unstructured":"Hirata, H. et al. The evolving genomic landscape of esophageal squamous cell carcinoma under chemoradiotherapy. Cancer Res 81, 4926\u20134938 (2021).","journal-title":"Cancer Res"},{"key":"2850_CR271","doi-asserted-by":"publisher","first-page":"101055","DOI":"10.1016\/j.xcrm.2023.101055","volume":"4","author":"P Cunnea","year":"2023","unstructured":"Cunnea, P. et al. Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: implications for surgical and clinical outcomes. Cell Rep. Med. 4, 101055 (2023).","journal-title":"Cell Rep. Med."},{"key":"2850_CR272","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","volume":"68","author":"EM Swisher","year":"2008","unstructured":"Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1<\/i> -mutated ovarian carcinomas with platinum resistance. Cancer Res 68, 2581\u20132586 (2008).","journal-title":"Cancer Res"},{"key":"2850_CR273","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24009-8","volume":"12","author":"EA Pietil\u00e4","year":"2021","unstructured":"Pietil\u00e4, E. A. et al. Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance. Nat. Commun. 12, 3904 (2021).","journal-title":"Nat. Commun."},{"key":"2850_CR274","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1158\/0008-5472.CAN-16-0980","volume":"76","author":"J-G Jung","year":"2016","unstructured":"Jung, J.-G. et al. Ovarian cancer chemoresistance relies on the stem cell reprogramming factor PBX1. Cancer Res 76, 6351\u20136361 (2016).","journal-title":"Cancer Res"},{"key":"2850_CR275","doi-asserted-by":"publisher","first-page":"6356","DOI":"10.1158\/1078-0432.CCR-11-0735","volume":"17","author":"DC Marchion","year":"2011","unstructured":"Marchion, D. C. et al. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin. Cancer Res. 17, 6356\u20136366 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2850_CR276","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1158\/0008-5472.CAN-14-2341","volume":"75","author":"F-G Ye","year":"2015","unstructured":"Ye, F.-G. et al. Cytidine deaminase axis modulated by miR-484 differentially regulates cell proliferation and chemoresistance in breast cancer. Cancer Res 75, 1504\u20131515 (2015).","journal-title":"Cancer Res"},{"key":"2850_CR277","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.celrep.2019.01.048","volume":"26","author":"S Seth","year":"2019","unstructured":"Seth, S. et al. Pre-existing functional heterogeneity of tumorigenic compartment as th e origin of chemoresistance in pancreatic tumors. Cell Rep 26, 1518\u20131532.e1519 (2019).","journal-title":"Cell Rep"},{"key":"2850_CR278","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","volume":"129","author":"D Rossi","year":"2017","unstructured":"Rossi, D. et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood 129, 1947\u20131957 (2017).","journal-title":"Blood"},{"key":"2850_CR279","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/CM9.0000000000001294","volume":"134","author":"L Wang","year":"2020","unstructured":"Wang, L. & Li, L.-R. R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms. Chin. Med. J. 134, 253\u2013260 (2020).","journal-title":"Chin. Med. J."},{"key":"2850_CR280","doi-asserted-by":"publisher","first-page":"i28","DOI":"10.1093\/annonc\/mdx705","volume":"29","author":"C Ricordel","year":"2018","unstructured":"Ricordel, C., Friboulet, L., Facchinetti, F. & Soria, J. C. Molecular mechanisms of acquired resistance to third-generation EGFR-T KIs in EGFR T790M-mutant lung cancer. Ann. Oncol. 29, i28\u2013i37 (2018).","journal-title":"Ann. Oncol."},{"key":"2850_CR281","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795\u2013801 (2015).","journal-title":"Nat. Med."},{"key":"2850_CR282","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi, A. et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat. Med. 28, 1612\u20131618 (2022).","journal-title":"Nat. Med."},{"key":"2850_CR283","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nm0495-348","volume":"1","author":"B Liu","year":"1995","unstructured":"Liu, B. et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat. Med. 1, 348\u2013352 (1995).","journal-title":"Nat. Med."},{"key":"2850_CR284","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41392-020-0120-3","volume":"5","author":"J Fahrer","year":"2020","unstructured":"Fahrer, J. Switching off DNA repair\u2014how colorectal cancer evades targeted therapies through adaptive mutability. Signal Transduct. Target. Ther. 5, 19 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2850_CR285","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","volume":"25","author":"KN Shah","year":"2019","unstructured":"Shah, K. N. et al. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat. Med. 25, 111\u2013118 (2019).","journal-title":"Nat. Med."},{"key":"2850_CR286","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).","journal-title":"Sci. Transl. Med."},{"key":"2850_CR287","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.xcrm.2020.100007","volume":"1","author":"N Roper","year":"2020","unstructured":"Roper, N. et al. Clonal evolution and heterogeneity of osimertinib-acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep. Med. 1, 100007 (2020).","journal-title":"Cell Rep. Med."},{"key":"2850_CR288","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.annonc.2022.01.004","volume":"33","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients. Ann. Oncol. 33, 434\u2013444 (2022).","journal-title":"Ann. Oncol."},{"key":"2850_CR289","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","volume":"182","author":"A Maynard","year":"2020","unstructured":"Maynard, A. et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182, 1232\u20131251.e1222 (2020).","journal-title":"Cell"},{"key":"2850_CR290","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/0008-5472.CAN-24-1703","volume":"85","author":"A Shea","year":"2025","unstructured":"Shea, A. et al. Modeling drug responses and evolutionary dynamics using patient-derived xenografts reveals precision medicine strategies for triple-negative breast cancer. Cancer Res 85, 567\u2013584 (2025).","journal-title":"Cancer Res"},{"key":"2850_CR291","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall, J. et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov 7, 1006\u20131017 (2017).","journal-title":"Cancer Discov"},{"key":"2850_CR292","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45478-7","volume":"15","author":"J Dai","year":"2024","unstructured":"Dai, J. et al. Tracing back primed resistance in cancer via sister cells. Nat. Commun. 15, 1158 (2024).","journal-title":"Nat. Commun."},{"key":"2850_CR293","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1158\/0008-5472.CAN-24-0293","volume":"84","author":"L Cadzow","year":"2024","unstructured":"Cadzow, L. et al. The USP1 inhibitor KSQ-4279 overcomes PARP inhibitor resistance in homologous recombination-deficient tumors. Cancer Res 84, 3419\u20133434 (2024).","journal-title":"Cancer Res"},{"key":"2850_CR294","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary, B. et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov 8, 1390\u20131403 (2018).","journal-title":"Cancer Discov"},{"key":"2850_CR295","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/2159-8290.CD-18-1084","volume":"8","author":"R Schiff","year":"2018","unstructured":"Schiff, R. & Jeselsohn, R. Is ctDNA the road map to the landscape of the clonal mutational evolution in drug resistance? Lessons from the PALOMA-3 study and implications for precision medicine. Cancer Discov 8, 1352\u20131354 (2018).","journal-title":"Cancer Discov"},{"key":"2850_CR296","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11729-1","volume":"10","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4\/6 inhibitor-resistant HER2-positive breast cancer. Nat. Commun. 10, 3817 (2019).","journal-title":"Nat. Commun."},{"key":"2850_CR297","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-023-00466-2","volume":"12","author":"Q Xu","year":"2023","unstructured":"Xu, Q. et al. Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy. Oncogenesis 12, 21 (2023).","journal-title":"Oncogenesis"},{"key":"2850_CR298","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-0719-6","volume":"12","author":"Q Zhou","year":"2020","unstructured":"Zhou, Q. et al. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. Genome Med 12, 20 (2020).","journal-title":"Genome Med"},{"key":"2850_CR299","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/ijc.31154","volume":"142","author":"M Yamauchi","year":"2018","unstructured":"Yamauchi, M. et al. Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients. Int. J. Cancer. 142, 1418\u20131426 (2018).","journal-title":"Int. J. Cancer."},{"key":"2850_CR300","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1158\/1078-0432.CCR-22-2305","volume":"28","author":"J Tsuji","year":"2022","unstructured":"Tsuji, J. et al. Clinical efficacy and whole-exome sequencing of liquid biopsies in a phase IB\/II study of bazedoxifene and palbociclib in advanced hormone receptor-positive breast cancer. Clin. Cancer Res. 28, 5066\u20135078 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2850_CR301","doi-asserted-by":"publisher","first-page":"e1601737","DOI":"10.1126\/sciadv.1601737","volume":"2","author":"EK Law","year":"2016","unstructured":"Law, E. K. et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci. Adv. 2, e1601737 (2016).","journal-title":"Sci. Adv."},{"key":"2850_CR302","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/annonc\/mdx483","volume":"29","author":"C Fribbens","year":"2018","unstructured":"Fribbens, C. et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann. Oncol. 29, 145\u2013153 (2018).","journal-title":"Ann. Oncol."},{"key":"2850_CR303","doi-asserted-by":"publisher","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","volume":"7","author":"G Schiavon","year":"2015","unstructured":"Schiavon, G. et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med. 7, 313ra182 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2850_CR304","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s43018-021-00215-7","volume":"2","author":"JI Griffiths","year":"2021","unstructured":"Griffiths, J. I. et al. Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4\/6 therapy. Nat. Cancer. 2, 658\u2013671 (2021).","journal-title":"Nat. Cancer."},{"key":"2850_CR305","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ng.3773","volume":"49","author":"L Magnani","year":"2017","unstructured":"Magnani, L. et al. Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER\u03b1 metastatic breast cancer. Nat. Genet. 49, 444\u2013450 (2017).","journal-title":"Nat. Genet."},{"key":"2850_CR306","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/annonc\/mdv282","volume":"26","author":"M Nakazawa","year":"2015","unstructured":"Nakazawa, M. et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann. Oncol. 26, 1859\u20131865 (2015).","journal-title":"Ann. Oncol."},{"key":"2850_CR307","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1158\/1078-0432.CCR-22-3736","volume":"29","author":"N Menssouri","year":"2023","unstructured":"Menssouri, N. et al. Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen receptor pathway inhibitors. Clin. Cancer Res. 29, 4504\u20134517 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2850_CR308","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1158\/1078-0432.CCR-21-1625","volume":"27","author":"M Annala","year":"2021","unstructured":"Annala, M. et al. Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition. Clin. Cancer Res. 27, 4610\u20134623 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2850_CR309","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949.e916 (2017).","journal-title":"Cell"},{"key":"2850_CR310","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01260-z","volume":"19","author":"L Horvath","year":"2020","unstructured":"Horvath, L. et al. Overcoming immunotherapy resistance in non-small cell lung cancer (NSC LC)\u2014novel approaches and future outlook. Mol. Cancer 19, 141 (2020).","journal-title":"Mol. Cancer"},{"key":"2850_CR311","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1038\/s41591-024-03240-y","volume":"30","author":"TJ Alban","year":"2024","unstructured":"Alban, T. J. et al. Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab. Nat. Med. 30, 3209\u20133222 (2024).","journal-title":"Nat. Med."},{"key":"2850_CR312","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01146-3","volume":"14","author":"M Golkaram","year":"2022","unstructured":"Golkaram, M. et al. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape. Genome Med 14, 143 (2022).","journal-title":"Genome Med"},{"key":"2850_CR313","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2017.10.027","volume":"171","author":"MC Andrews","year":"2017","unstructured":"Andrews, M. C. & Wargo, J. A. Cancer Evolution during Immunotherapy. Cell 171, 740\u2013742 (2017).","journal-title":"Cell"},{"key":"2850_CR314","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462\u2013469 (2019).","journal-title":"Nat. Med."},{"key":"2850_CR315","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri, A. et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol. Cancer. 22, 40 (2023).","journal-title":"Mol. Cancer."},{"key":"2850_CR316","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13046-020-01721-9","volume":"39","author":"S Camelliti","year":"2020","unstructured":"Camelliti, S. et al. Mechanisms of hyperprogressive disease after immune checkpoint inhibit or therapy: what we (don\u2019t) know. J. Exp. Clin. Cancer Res. 39, 236 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2850_CR317","doi-asserted-by":"publisher","first-page":"810472","DOI":"10.3389\/fnut.2022.810472","volume":"9","author":"X Liu","year":"2022","unstructured":"Liu, X. & Qiao, L. Hyperprogressive disease in malignant carcinoma with immune checkpoint inhibitor use: a review. Front. Nutr. 9, 810472 (2022).","journal-title":"Front. Nutr."},{"key":"2850_CR318","doi-asserted-by":"publisher","first-page":"e008677","DOI":"10.1136\/jitc-2023-008677","volume":"12","author":"JE Willoughby","year":"2024","unstructured":"Willoughby, J. E. et al. Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations. J. Immunother. Cancer 12, e008677 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2850_CR319","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"Giuseppe","year":"2019","unstructured":"Giuseppe et al. Antibody\u2013Fc\/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non\u2013small Cell Lung Cancer Subsequent to PD-1\/PD-L1 Blockade. Clin Cancer Res. 25, 989\u2013999 (2019).","journal-title":"Clin Cancer Res."},{"key":"2850_CR320","doi-asserted-by":"publisher","first-page":"v405","DOI":"10.1093\/annonc\/mdx376.006","volume":"28","author":"AK Singavi","year":"2017","unstructured":"Singavi, A. K. et al. Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) \u2013 analysis of somatic alterations (SAs). Ann. Oncol. 28, v405 (2017).","journal-title":"Ann. Oncol."},{"key":"2850_CR321","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","volume":"72","author":"W Peng","year":"2012","unstructured":"Peng, W. et al. PD-1 Blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible chemokines. Cancer Res 72, 5209\u20135218 (2012).","journal-title":"Cancer Res"},{"key":"2850_CR322","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/ijc.31744","volume":"144","author":"Z Yin","year":"2019","unstructured":"Yin, Z., Li, C., Wang, J. & Xue, L. Myeloid-derived suppressor cells: roles in the tumor microenvironment and tumor radiotherapy. Int. J. Cancer 144, 933\u2013946 (2019).","journal-title":"Int. J. Cancer"},{"key":"2850_CR323","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/0008-5472.CAN-24-3281","volume":"85","author":"ES Blomain","year":"2025","unstructured":"Blomain, E. S. et al. Evolutionary pressures shape undifferentiated pleomorphic sarcoma development and radiotherapy response. Cancer Res 85, 1162\u20131174 (2025).","journal-title":"Cancer Res"},{"key":"2850_CR324","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1109\/TMI.2014.2301892","volume":"33","author":"H Mi","year":"2014","unstructured":"Mi, H. et al. Prediction of lung tumor evolution during radiotherapy in individual patients with PET. IEEE Trans. Med. Imaging 33, 995\u20131003 (2014).","journal-title":"IEEE Trans. Med. Imaging"},{"key":"2850_CR325","doi-asserted-by":"publisher","first-page":"24196","DOI":"10.1073\/pnas.1907860116","volume":"116","author":"S Premi","year":"2019","unstructured":"Premi, S. et al. Genomic sites hypersensitive to ultraviolet radiation. Proc. Natl. Acad. Sci. USA 116, 24196\u201324205 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR326","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrm3822","volume":"15","author":"JA Marteijn","year":"2014","unstructured":"Marteijn, J. A. et al. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol. 15, 465\u2013481 (2014).","journal-title":"Nat Rev Mol Cell Biol."},{"key":"2850_CR327","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-023-06156-8","volume":"618","author":"GK Griffin","year":"2023","unstructured":"Griffin, G. K. et al. Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature 618, 834\u2013841 (2023).","journal-title":"Nature"},{"key":"2850_CR328","doi-asserted-by":"publisher","first-page":"eadh3083","DOI":"10.1126\/sciadv.adh3083","volume":"9","author":"N Adler","year":"2023","unstructured":"Adler, N. et al. Mutational processes of tobacco smoking and APOBEC activity generate protein-truncating mutations in cancer genomes. Sci. Adv. 9, eadh3083 (2023).","journal-title":"Sci. Adv."},{"key":"2850_CR329","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1253462","volume":"346","author":"EC Bruin","year":"2014","unstructured":"Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes define s lung cancer evolution. Science 346, 251\u2013256 (2014).","journal-title":"Science"},{"key":"2850_CR330","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cell.2023.03.013","volume":"186","author":"CE Weeden","year":"2023","unstructured":"Weeden, C. E. et al. Impact of risk factors on early cancer evolution. Cell 186, 1541\u20131563 (2023).","journal-title":"Cell"},{"key":"2850_CR331","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05467-z","volume":"9","author":"S Wu","year":"2018","unstructured":"Wu, S., Zhu, W., Thompson, P. & Hannun, Y. A. Evaluating intrinsic and non-intrinsic cancer risk factors. Nat. Commun. 9, 3490 (2018).","journal-title":"Nat. Commun."},{"key":"2850_CR332","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02887-7","volume":"7","author":"G Yan","year":"2017","unstructured":"Yan, G. et al. Chronic alcohol consumption promotes diethylnitrosamine-induced hepatocarcinogenesis via immune disturbances. Sci. Rep. 7, 2567 (2017).","journal-title":"Sci. Rep."},{"key":"2850_CR333","first-page":"197","volume":"42","author":"F Francescangeli","year":"2023","unstructured":"Francescangeli, F. et al. Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution. Cancer Metast. Rev. 42, 197\u2013215 (2023).","journal-title":"Cancer Metast. Rev."},{"key":"2850_CR334","doi-asserted-by":"publisher","first-page":"e2306776121","DOI":"10.1073\/pnas.2306776121","volume":"121","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. A high-fat diet promotes cancer progression by inducing gut microbiota-mediated leucine production and PMN-MDSC differentiation. Proc. Natl. Acad. Sci. USA 121, e2306776121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2850_CR335","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1126\/science.aab4082","volume":"349","author":"I Martincorena","year":"2015","unstructured":"Martincorena, I. & Campbell, P. J. Somatic mutation in cancer and normal cells. Science 349, 1483\u20131489 (2015).","journal-title":"Science"},{"key":"2850_CR336","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.ccell.2023.11.003","volume":"41","author":"J Chang","year":"2023","unstructured":"Chang, J. et al. Genomic alterations driving precancerous to cancerous lesions in esophageal cancer development. Cancer Cell 41, 2038\u20132050.e2035 (2023).","journal-title":"Cancer Cell"},{"key":"2850_CR337","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1158\/1078-0432.CCR-13-2345","volume":"20","author":"MH Voss","year":"2014","unstructured":"Voss, M. H. et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin. Cancer Res. 20, 1955\u20131964 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2850_CR338","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1126\/science.aau3879","volume":"362","author":"I Martincorena","year":"2018","unstructured":"Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911\u2013917 (2018).","journal-title":"Science"},{"key":"2850_CR339","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2850_CR340","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/255197a0","volume":"255","author":"J Cairns","year":"1975","unstructured":"Cairns, J. Mutation selection and the natural history of cancer. Nature 255, 197\u2013200 (1975).","journal-title":"Nature"},{"key":"2850_CR341","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52\u201367 (2010).","journal-title":"Cell"},{"key":"2850_CR342","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado, H. et al. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer 17, 302\u2013317 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2850_CR343","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nature09515","volume":"467","author":"S Yachida","year":"2010","unstructured":"Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114\u20131117 (2010).","journal-title":"Nature"},{"key":"2850_CR344","doi-asserted-by":"crossref","unstructured":"Akala, O. O. et al. Long-term haematopoietic reconstitution by Trp53-\/-p16Ink4a-\/-p19Arf-\/-multipotent progenitors. Nature 453, 228\u2013232 (2008).","DOI":"10.1038\/nature06869"},{"key":"2850_CR345","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jtbi.2014.02.025","volume":"355","author":"J Foo","year":"2014","unstructured":"Foo, J. & Michor, F. Evolution of acquired resistance to anti-cancer therapy. J. Theor. Biol. 355, 10\u201320 (2014).","journal-title":"J. Theor. Biol."},{"key":"2850_CR346","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1177\/0091270005276905","volume":"45","author":"VS Donnenberg","year":"2005","unstructured":"Donnenberg, V. S. & Donnenberg, A. D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J. Clin. Pharmacol. 45, 872\u2013877 (2005).","journal-title":"J. Clin. Pharmacol."},{"key":"2850_CR347","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.tcb.2019.03.003","volume":"29","author":"K Hinohara","year":"2019","unstructured":"Hinohara, K. & Polyak, K. Intratumoral heterogeneity: more than just mutations. Trends Cell Biol 29, 569\u2013579 (2019).","journal-title":"Trends Cell Biol"},{"key":"2850_CR348","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2714","volume":"9","author":"MB Meads","year":"2009","unstructured":"Meads, M. B., Gatenby, R. A. & Dalton, W. S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9, 665\u2013674 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"2850_CR349","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake, T. L. & Vetrie, D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129, 1595\u20131606 (2017).","journal-title":"Blood"},{"key":"2850_CR350","doi-asserted-by":"publisher","first-page":"20130020","DOI":"10.1098\/rsfs.2013.0020","volume":"3","author":"D Basanta","year":"2013","unstructured":"Basanta, D. & Anderson, A. R. A. Exploiting ecological principles to better understand cancer progression and treatment. Interface Focus 3, 20130020 (2013).","journal-title":"Interface Focus"},{"key":"2850_CR351","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","volume":"16","author":"T O\u2019Hare","year":"2006","unstructured":"O\u2019Hare, T., Corbin, A. S. & Druker, B. J. Targeted CML therapy: controlling drug resistance, seeking cure. Curr. Opin. Genet. Dev. 16, 92\u201399 (2006).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2850_CR352","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.gde.2008.01.004","volume":"18","author":"JA Engelman","year":"2008","unstructured":"Engelman, J. A. & Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73\u201379 (2008).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2850_CR353","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","volume":"30","author":"KL Blackwell","year":"2012","unstructured":"Blackwell, K. L. et al. Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2\u2013Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study. J Clin Oncol. 30, 2585\u20132592 (2012).","journal-title":"J Clin Oncol."},{"key":"2850_CR354","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1677\/erc.1.01273","volume":"13","author":"S Massarweh","year":"2006","unstructured":"Massarweh, S. & Schiff, R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor\/growth factor signaling crosstalk. Endocr. Relat. Cancer 13, S15\u2013S24 (2006).","journal-title":"Endocr. Relat. Cancer"},{"key":"2850_CR355","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.cmet.2019.05.003","volume":"30","author":"DJ Puleston","year":"2019","unstructured":"Puleston, D. J. et al. Polyamines and eIF5A hypusination modulate mitochondrial respiration a nd macrophage activation. Cell Metab 30, 352\u2013363.e358 (2019).","journal-title":"Cell Metab"},{"key":"2850_CR356","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812\u2013830.e814 (2018).","journal-title":"Immunity"},{"key":"2850_CR357","first-page":"796","volume":"19","author":"JP Antonios","year":"2017","unstructured":"Antonios, J. P. et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1\/PD-L1 mechanism in glioblastoma. Neuro Oncol 19, 796\u2013807 (2017).","journal-title":"Neuro Oncol"},{"key":"2850_CR358","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ymthe.2016.10.003","volume":"25","author":"N Kamran","year":"2017","unstructured":"Kamran, N. et al. Immunosuppressive myeloid cells\u2019 blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy. Mol. Ther. 25, 232\u2013248 (2017).","journal-title":"Mol. Ther."},{"key":"2850_CR359","doi-asserted-by":"publisher","first-page":"eabc8929","DOI":"10.1126\/sciadv.abc8929","volume":"7","author":"J Miska","year":"2021","unstructured":"Miska, J. et al. Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma. Sci. Adv. 7, eabc8929 (2021).","journal-title":"Sci. Adv."},{"key":"2850_CR360","doi-asserted-by":"publisher","first-page":"6925","DOI":"10.1158\/0008-5472.CAN-14-1249","volume":"74","author":"A Brett-Morris","year":"2014","unstructured":"Brett-Morris, A. et al. The polyamine catabolic enzyme SAT1 modulates tumorigenesis and radiation response in GBM. Cancer Res 74, 6925\u20136934 (2014).","journal-title":"Cancer Res"},{"key":"2850_CR361","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jid.2021.08.434","volume":"142","author":"G Chhabra","year":"2022","unstructured":"Chhabra, G. et al. Antimelanoma effects of concomitant inhibition of SIRT1 and SIRT3 in B rafV600E\/PtenNULL Mice. J. Investig. Dermatol. 142, 1145\u20131157.e1147 (2022).","journal-title":"J. Investig. Dermatol."},{"key":"2850_CR362","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03925-x","volume":"21","author":"L Wu","year":"2023","unstructured":"Wu, L. et al. Sirt3 restricts tumor initiation via promoting LONP1 deacetylation and K63 ubiquitination. J. Transl. Med. 21, 81 (2023).","journal-title":"J. Transl. Med."},{"key":"2850_CR363","doi-asserted-by":"publisher","first-page":"e56052","DOI":"10.15252\/embr.202256052","volume":"24","author":"J Jin","year":"2023","unstructured":"Jin, J. et al. SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth. EMBO Rep 24, e56052 (2023).","journal-title":"EMBO Rep"},{"key":"2850_CR364","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.tips.2023.12.005","volume":"45","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Context-dependent role of SIRT3 in cancer. Trends Pharmacol. Sci. 45, 173\u2013190 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"2850_CR365","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.592","volume":"11","author":"J Shi","year":"2021","unstructured":"Shi, J. et al. HIF2\u03b1 promotes tumour growth in clear cell renal cell carcinoma by increasing the expression of NUDT1 to reduce oxidative stress. Clin. Transl. Med. 11, e592 (2021).","journal-title":"Clin. Transl. Med."},{"key":"2850_CR366","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ptr.7608","volume":"37","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Resveratrol reverses TGF-\u03b21-mediated invasion and metastasis of breast cancer cells via the SIRT3\/AMPK\/autophagy signal axis. Phytother. Res. 37, 211\u2013230 (2023).","journal-title":"Phytother. Res."},{"key":"2850_CR367","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.yexcr.2018.01.036","volume":"364","author":"R Li","year":"2018","unstructured":"Li, R., Quan, Y. & Xia, W. SIRT3 inhibits prostate cancer metastasis through regulation of FOXO3A by suppressing Wnt\/\u03b2-catenin pathway. Exp. Cell Res. 364, 143\u2013151 (2018).","journal-title":"Exp. Cell Res."},{"key":"2850_CR368","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ccell.2019.05.002","volume":"35","author":"M Li","year":"2019","unstructured":"Li, M. et al. Non-oncogene addiction to SIRT3 plays a critical role in lymphomagenesis. Cancer Cell 35, 916\u2013931.e919 (2019).","journal-title":"Cancer Cell"},{"key":"2850_CR369","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13046-022-02310-8","volume":"41","author":"Z Ma","year":"2022","unstructured":"Ma, Z. et al. ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3\/p53 signaling pathway. J. Exp. Clin. Cancer Res. 41, 130 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2850_CR370","doi-asserted-by":"publisher","first-page":"8315","DOI":"10.7150\/thno.45922","volume":"10","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics 10, 8315\u20138342 (2020).","journal-title":"Theranostics"},{"key":"2850_CR371","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/mc.23080","volume":"58","author":"J George","year":"2019","unstructured":"George, J., Nihal, M., Singh, C. K. & Ahmad, N. 4\u2019-Bromo-resveratrol, a dual Sirtuin-1 and Sirtuin-3 inhibitor, inhibits melanoma cell growth through mitochondrial metabolic reprogramming. Mol. Carcinog. 58, 1876\u20131885 (2019).","journal-title":"Mol. Carcinog."},{"key":"2850_CR372","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.chembiol.2013.09.019","volume":"20","author":"GTT Nguyen","year":"2013","unstructured":"Nguyen, G. T. T., Gertz, M. & Steegborn, C. Crystal structures of Sirt3 complexes with 4\u2019-bromo-resveratrol reveal binding sites and inhibition mechanism. Chem. Biol. 20, 1375\u20131385 (2013).","journal-title":"Chem. Biol."},{"key":"2850_CR373","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejmech.2012.07.001","volume":"55","author":"U Galli","year":"2012","unstructured":"Galli, U. et al. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2. Eur. J. Med. Chem. 55, 58\u201366 (2012).","journal-title":"Eur. J. Med. Chem."},{"key":"2850_CR374","doi-asserted-by":"publisher","first-page":"14192","DOI":"10.1021\/acs.jmedchem.0c02268","volume":"64","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Structure-guided design of a small-molecule activator of Sirtuin-3 that modulates autophagy in triple-negative breast cancer. J. Med. Chem. 64, 14192\u201314216 (2021).","journal-title":"J. Med. Chem."},{"key":"2850_CR375","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3389\/fphar.2017.00199","volume":"8","author":"L-X Luo","year":"2017","unstructured":"Luo, L.-X. et al. Honokiol induces apoptosis, G1 Arrest, and autophagy in KRAS mutant lung cancer cells. Front. Pharmacol. 8, 199 (2017).","journal-title":"Front. Pharmacol."},{"key":"2850_CR376","doi-asserted-by":"publisher","first-page":"109563","DOI":"10.1016\/j.biopha.2019.109563","volume":"121","author":"W Li","year":"2020","unstructured":"Li, W. et al. Berberine increases glucose uptake and intracellular ROS levels by promoting Sirtuin 3 ubiquitination. Biomed. Pharmacother. 121, 109563 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"2850_CR377","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature11881","volume":"494","author":"MB Burns","year":"2013","unstructured":"Burns, M. B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366\u2013370 (2013).","journal-title":"Nature"},{"key":"2850_CR378","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1371\/journal.pgen.0030063","volume":"3","author":"JM Kidd","year":"2007","unstructured":"Kidd, J. M. et al. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 3, e63 (2007).","journal-title":"PLoS Genet"},{"key":"2850_CR379","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15024","volume":"8","author":"T Kouno","year":"2017","unstructured":"Kouno, T. et al. Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity. Nat. Commun. 8, 15024 (2017).","journal-title":"Nat. Commun."},{"key":"2850_CR380","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nsmb.3344","volume":"24","author":"K Shi","year":"2017","unstructured":"Shi, K. et al. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat. Struct. Mol. Biol. 24, 131\u2013139 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2850_CR381","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s42003-021-01844-5","volume":"4","author":"A Rouf Banday","year":"2021","unstructured":"Rouf Banday, A. et al. Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity. Commun. Biol. 4, 386 (2021).","journal-title":"Commun. Biol."},{"key":"2850_CR382","doi-asserted-by":"publisher","first-page":"831146","DOI":"10.3389\/fgene.2022.831146","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang, F., Dong, X., Yang, F. & Xing, N. Comparative analysis of differentially mutated genes in non-muscle and muscle-invasive bladder cancer in the Chinese population by whole exome sequencing. Front. Genet. 13, 831146 (2022).","journal-title":"Front. Genet."},{"key":"2850_CR383","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/med.21649","volume":"40","author":"JJ Wu","year":"2020","unstructured":"Wu, J. J. et al. Agonists and inhibitors of the STING pathway: potential agents for immunotherapy. Med. Res. Rev. 40, 1117\u20131141 (2020).","journal-title":"Med. Res. Rev."},{"key":"2850_CR384","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/s43018-021-00268-8","volume":"2","author":"SM W\u00f6rmann","year":"2021","unstructured":"W\u00f6rmann, S. M. et al. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Nat. Cancer 2, 1338\u20131356 (2021).","journal-title":"Nat. Cancer"},{"key":"2850_CR385","doi-asserted-by":"publisher","first-page":"283ra254","DOI":"10.1126\/scitranslmed.aaa1408","volume":"7","author":"N McGranahan","year":"2015","unstructured":"McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra254 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2850_CR386","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","volume":"5","author":"C Swanton","year":"2015","unstructured":"Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov 5, 704\u2013712 (2015).","journal-title":"Cancer Discov"},{"key":"2850_CR387","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.chembiol.2017.10.007","volume":"25","author":"ME Olson","year":"2018","unstructured":"Olson, M. E., Harris, R. S. & Harki, D. A. APOBEC enzymes as targets for virus and cancer therapy. Cell Chem. Biol. 25, 36\u201349 (2018).","journal-title":"Cell Chem. Biol."},{"key":"2850_CR388","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14568-7","volume":"11","author":"CB Driscoll","year":"2020","unstructured":"Driscoll, C. B. et al. APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nat. Commun. 11, 790 (2020).","journal-title":"Nat. Commun."},{"key":"2850_CR389","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-21-0146","volume":"10","author":"AV DiMarco","year":"2022","unstructured":"DiMarco, A. V. et al. APOBEC mutagenesis inhibits breast cancer growth through induction of T cell-mediated antitumor immune responses. Cancer Immunol. Res. 10, 70\u201386 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"2850_CR390","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/bjc.2017.133","volume":"117","author":"J Nikkil\u00e4","year":"2017","unstructured":"Nikkil\u00e4, J. et al. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. Br. J. Cancer 117, 113\u2013123 (2017).","journal-title":"Br. J. Cancer"},{"key":"2850_CR391","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1158\/0008-5472.CAN-16-3389","volume":"77","author":"R Buisson","year":"2017","unstructured":"Buisson, R., Lawrence, M. S., Benes, C. H. & Zou, L. APOBEC3A and APOBEC3B activities render cancer cells susceptible to ATR inhibition. Cancer Res 77, 4567\u20134578 (2017).","journal-title":"Cancer Res"},{"key":"2850_CR392","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1158\/0008-5472.CAN-16-3394","volume":"77","author":"AM Green","year":"2017","unstructured":"Green, A. M. et al. Cytosine deaminase APOBEC3A sensitizes leukemia cells to inhibition of the DNA replication checkpoint. Cancer Res 77, 4579\u20134588 (2017).","journal-title":"Cancer Res"},{"key":"2850_CR393","doi-asserted-by":"publisher","first-page":"zcaa033","DOI":"10.1093\/narcan\/zcaa033","volume":"2","author":"KL Conner","year":"2020","unstructured":"Conner, K. L. et al. APOBEC3 enzymes mediate the efficacy of cisplatin and are epistatic with base excision repair and mismatch repair in platinum response. NAR Cancer 2, zcaa033 (2020).","journal-title":"NAR Cancer"},{"key":"2850_CR394","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2159-8290.CD-21-1434","volume":"12","author":"G Crisafulli","year":"2022","unstructured":"Crisafulli, G. et al. Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov 12, 1656\u20131675 (2022).","journal-title":"Cancer Discov"},{"key":"2850_CR395","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.21.02583","volume":"40","author":"F Morano","year":"2022","unstructured":"Morano, F. et al. Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial. J. Clin. Oncol. 40, 1562\u20131573 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2850_CR396","doi-asserted-by":"publisher","first-page":"e00747","DOI":"10.7554\/eLife.00747","volume":"2","author":"I Bozic","year":"2013","unstructured":"Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747 (2013).","journal-title":"eLife"},{"key":"2850_CR397","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1158\/2159-8290.CD-15-0063","volume":"5","author":"EM Tricker","year":"2015","unstructured":"Tricker, E. M. et al. Combined EGFR\/MEK inhibition prevents the emergence of resistance in < i>EGFR-mutant lung cancer. Cancer Discov 5, 960\u2013971 (2015).","journal-title":"Cancer Discov"},{"key":"2850_CR398","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s12276-025-01493-2","volume":"57","author":"N Yu","year":"2025","unstructured":"Yu, N. et al. Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor-tyrosine kinase inhibitor resistance subclones. Exp. Mol. Med. 57, 1567\u20131578 (2025).","journal-title":"Exp. Mol. Med."},{"key":"2850_CR399","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17, 425\u2013439 (2016).","journal-title":"Lancet Oncol"},{"key":"2850_CR400","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1158\/1078-0432.CCR-14-3312","volume":"21","author":"HJ Jacobsen","year":"2015","unstructured":"Jacobsen, H. J. et al. Pan-HER, an antibody mixture simultaneously targeting EGFR, HER2, and HER3, effectively overcomes tumor heterogeneity and plasticity. Clin. Cancer Res. 21, 4110\u20134122 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2850_CR401","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1158\/2159-8290.CD-17-0177","volume":"7","author":"CF Malone","year":"2017","unstructured":"Malone, C. F. et al. mTOR and HDAC inhibitors converge on the TXNIP\/thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors. Cancer Discov 7, 1450\u20131463 (2017).","journal-title":"Cancer Discov"},{"key":"2850_CR402","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01968-5","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 8, 1816 (2017).","journal-title":"Nat. Commun."},{"key":"2850_CR403","doi-asserted-by":"publisher","first-page":"e091262","DOI":"10.1136\/bmjopen-2024-091262","volume":"14","author":"UA Mukherjee","year":"2024","unstructured":"Mukherjee, U. A. et al. Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer. BMJ Open 14, e091262 (2024).","journal-title":"BMJ Open"},{"key":"2850_CR404","doi-asserted-by":"crossref","unstructured":"Enriquez-Navas, P. M. et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl. Med. 8, (2016).","DOI":"10.1126\/scitranslmed.aad7842"},{"key":"2850_CR405","doi-asserted-by":"publisher","first-page":"e84263","DOI":"10.7554\/eLife.84263","volume":"12","author":"J West","year":"2023","unstructured":"West, J. et al. A survey of open questions in adaptive therapy: bridging mathematics a nd clinical translation. eLife 12, e84263 (2023).","journal-title":"eLife"},{"key":"2850_CR406","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.chempr.2023.12.019","volume":"10","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. Development of tumor-evolution-targeted anticancer therapeutic nanomedicine EVT. Chem 10, 1337\u20131356 (2024).","journal-title":"Chem"},{"key":"2850_CR407","doi-asserted-by":"publisher","first-page":"e202203546","DOI":"10.1002\/anie.202203546","volume":"61","author":"F Ding","year":"2022","unstructured":"Ding, F. et al. Restoration of the immunogenicity of tumor cells for enhanced cancer therapy via nanoparticle-mediated copper chaperone inhibition. Angew. Chem. Int. Ed. 61, e202203546 (2022).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2850_CR408","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2017.02.007","volume":"44","author":"CAM La Porta","year":"2017","unstructured":"La Porta, C. A. M. & Zapperi, S. Complexity in cancer stem cells and tumor evolution: toward precision medicine. Semin. Cancer Biol. 44, 3\u20139 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"2850_CR409","doi-asserted-by":"publisher","first-page":"17793","DOI":"10.1021\/acsami.6b04403","volume":"8","author":"ST Ning","year":"2016","unstructured":"Ning, S. T. et al. Targeting colorectal cancer stem-like cells with anti-CD133 antibody-conjugated SN-38 nanoparticles. ACS Appl. Mater. Interfaces 8, 17793\u201317804 (2016).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2850_CR410","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12951-018-0424-4","volume":"16","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Specific cancer stem cell-therapy by albumin nanoparticles functionalized with CD44-mediated targeting. J Nanobiotechnol 16, 99 (2018).","journal-title":"J Nanobiotechnol"},{"key":"2850_CR411","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/10717544.2018.1507057","volume":"26","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid. Drug Deliv 26, 12\u201322 (2019).","journal-title":"Drug Deliv"},{"key":"2850_CR412","doi-asserted-by":"publisher","first-page":"15276","DOI":"10.1021\/acsnano.0c05589","volume":"14","author":"Y Geng","year":"2020","unstructured":"Geng, Y. et al. Differentiation of cancer stem cells through nanoparticle surface engineering. ACS Nano 14, 15276\u201315285 (2020).","journal-title":"ACS Nano"},{"key":"2850_CR413","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.actbio.2023.02.015","volume":"160","author":"K Wu","year":"2023","unstructured":"Wu, K. et al. An iron oxyhydroxide-based nanosystem sensitizes ferroptosis by a \u201cThree-Pronged\u201d strategy in breast cancer stem cells. Acta Biomater 160, 281\u2013296 (2023).","journal-title":"Acta Biomater"},{"key":"2850_CR414","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34760-1","volume":"13","author":"S P\u00e9nisson","year":"2022","unstructured":"P\u00e9nisson, S., Lambert, A. & Tomasetti, C. Evaluating cancer etiology and risk with a mathematical model of tumor evolution. Nat. Commun. 13, 7224 (2022).","journal-title":"Nat. Commun."},{"key":"2850_CR415","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2850_CR416","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41565-021-00962-9","volume":"16","author":"X Sun","year":"2021","unstructured":"Sun, X. et al. Amplifying STING activation by cyclic dinucleotide\u2013manganese particles for local and systemic cancer metalloimmunotherapy. Nat. Nanotechnol. 16, 1260\u20131270 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"2850_CR417","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/2159-8290.CD-18-0432","volume":"8","author":"TT Kwan","year":"2018","unstructured":"Kwan, T. T. et al. A digital RNA signature of circulating tumor cells predicting early therapeutic response in localized and metastatic breast cancer. Cancer Discov 8, 1286\u20131299 (2018).","journal-title":"Cancer Discov"},{"key":"2850_CR418","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2016.11.008","volume":"45","author":"CIE Smith","year":"2017","unstructured":"Smith, C. I. E. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). Semin. Cancer Biol. 45, 36\u201349 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"2850_CR419","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0632-z","volume":"11","author":"MW Fittall","year":"2019","unstructured":"Fittall, M. W. & Van Loo, P. Translating insights into tumor evolution to clinical practice: promises and challenges. Genome Med 11, 20 (2019).","journal-title":"Genome Med"},{"key":"2850_CR420","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1126\/science.abn0478","volume":"377","author":"JM Chan","year":"2022","unstructured":"Chan, J. M. et al. Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science 377, 1180\u20131191 (2022).","journal-title":"Science"},{"key":"2850_CR421","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1158\/0008-5472.CAN-25-0351","volume":"85","author":"H Hockings","year":"2025","unstructured":"Hockings, H. et al. Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control. Cancer Res. 85, 3503\u20133517 (2025).","journal-title":"Cancer Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02850-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02850-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02850-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T23:02:04Z","timestamp":1784502124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02850-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":421,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02850-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. Schematic diagrams were created with biorender.com.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"280"}}